Disrupting dynamic f-actin enhances skeletal muscle contraction due to mechanical softening by Sivathanu, Vivek




B.Tech. Mechanical Engineering (2010), Indian Institute of Technology, Madras
S.M. Mechanical Engineering (2013), M.I.T.
Submitted to the Department of Mechanical Engineering
in Partial Fulfillment of the Requirements for the Degree of
Doctor of Philosophy in Mechanical Engineering
at the
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
MASSACH SETS INSTITUTEOF TECHNOLOGY
FEB 0 9 2018
LIBRARIES
February 2018










Professor of Mechanical Engineering




Chairman, Committee on Graduate Students





Due to the condition of the original material, there are unavoidable
flaws in this reproduction. We have made every effort possible to
provide you with the best copy available.
Thank you.
The images contained in this document are of the
best quality available.
2




Submitted to the Department of Mechanical Engineering
on January 08, 2018 in Partial Fulfillment of the Requirements for the Degree of
Doctor of Philosophy in Mechanical Engineering
ABSTRA CT
Skeletal muscle wasting disorders such as sarcopenia affect the daily mobility of millions of aging people
globally due to decreased muscle mass and decreased muscle efficiency. In this study we discover a
novel target to improve the efficiency of skeletal muscle by targeting the dynamic f-actin cytoskeleton.
Using two model systems, an ex-vivo mouse muscle model and a novel in vitro optogenetic skeletal
muscle micro-tissue model, we show that disruption of the dynamic f-actin cytoskeleton using small
molecule actin dynamics inhibitors leads to a persistent 2-fold improvement in muscle active
contractility. We explored possible drawbacks of f-actin disruption, including loss of mechanical
integrity, cell death, and intracellular organelle damage. None of these downsides actually present
themselves with f-actin disruption. Muscle fatigue resistance however does seem to be slightly affected.
We performed a detailed characterization of the cytoskeletal modifications that occur during f-actin
disruption using dose-response-recovery studies, live f-actin imaging, fluorescence recovery after
photobleaching and more targeted f-actin disruption. Using these studies we conclude that treatments
which shorten f-actin filaments seem to improve contraction. We also uncovered previously unidentified
roles of branched and tropomyosin stabilized f-actin in force transmission.
Biomechanical testing at the cell level using AFM and at the tissue level using a micro-tensile test shows
a drop in mechanical stiffness that correlates well with a corresponding improvement in muscle force.
We ruled out a range of alternate hypotheses involving changes to sarcomeric proteins and energetic
activity, that could explain the force improvement, concluding that the force improvement due to f-actin
disruption is due to mechanical softening of the cells which pose to a lower resistance to their own
contraction. As a potential application, we show that a weak 3D printed muscle powered biological robot
starts walking with f-actin disruption. This target has significant therapeutic potential in muscle
disorders due to its disease non-specificity. We conclude by discussing possible future experiments that
could reveal the best therapeutic applications.
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Fig. 0: US population demographics aged 60+ (U.S. Bureau of the Census)
Fig. 1. Cow with defective myostatin gene, as well as myostatin knockout mice displaying
increased muscle mass
Fig.2: The unclear role of the non-sarcomeric f-actin in skeletal muscle force transmission. (A)
Figure from 74. Protein binding studies have led to the hypothesis that f-actin links the
sarcomeres to the costameres (which are the sites of connection of myotubes to extracellular
sites). If this f-actin link is critical, disrupting non-sarcomeric f-actin may negatively affect
force transmission. (B) Alternatively the non-sarcomeric f-actin may make the cell more rigid
mechanically impeding contraction. In the Hill muscle model shown, the non-sarcomeric f-
actin may contribute additional mechanical resistance to the parallel element, thereby
mechanically posing an additional barrier to muscle contraction. In this case, disrupting the
non-sarcomeric f-actin may enhance muscle contraction.
Fig. 3: Euthanized 2-3 month old wild type male mouse with skin removed ready for muscle
dissection. Dissection was complete within an hour of sacrificing the animal.
Fig. 4: EDL Muscle dissection from the hindlimb. (A-E): Sequential steps of dissection involving
removing the tibialis anterior muscle as well as isolating the EDL muscle from the rest of the
muscle belly. (F): dissection of the proximal tendon of the EDL muscle.
Fig. 5: Tissue mount for the EDL muscle explant with adjustable length and built-in electrodes
for electrical stimulation. (A and B) The CAD models show the top (A) and bottom (B) of the
assembly respectively, with the slidable anchor that is used to adjust the resting length of the
muscle. (C) Kapton based cantilevers are held together with an acrylic-silicone-acrylic
sandwich and inserted in to the rectangular through-holes of the anchor. Furthermore, an EDL
muscle tissue is bonded to the cantilever anchors as shown (D) An Arduino and motor driver
setup is used for electrical stimulation of the muscle tissue.
Fig. 6: Overall EDL muscle explant assembly connected to a circuit for electrical stimulation.
(A) Zoomed-out view of the tissue mount with the EDL muscle connected to the
micromanipulator for length adjustment. (B) Zoomed-in view showing the mounted EDL
muscle with platinum wire electrodes on either side of the muscle
Fig. 7: CytoD disrupts f-actin in mouse explant muscle tissues. (A) Phalloidin (Alexfluor 647)
stained tissues of muscle EDL explants with CytoD 3[tM or DMSO for 1 hour reveal that CytoD
does disrupt the f-actin structures as reflected by lower phalloidin intensity under identical
fluorescence microscopy settings. Scalebar is 60jim. (B) The intensity changes were quantified
with respected to the mean DMSO intensity (n=6). The changes are statistically significant, as
analyzed by a one-tailed 2-sample t-test p = 7.59*10-6
Fig. 8: Decline of EDL muscle explant contractility with time, normalized with respect to the
contractility at 60mins. The two colored envelopes represent the 68% and 95% confidence
intervals (1 and 2 sigma) of the data. The data represents the average and variation of 14
explant samples.
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Fig. 9: About half of the CytoD treated tissues (n=5) decline in contraction just like DMSO
treated controls (n=5). The natural decline of all tissues was measured once every 10 minutes
for 1 hour. After 1 hour, either DMSO or CytoD 3pM was applied to the tissues. The two colored
envelopes of each kind grey, blue and red each represent the 68% and 95% confidence
intervals (1 and 2 sigma) of the corresponding data
Fig. 10: About half of the CytoD treated tissues (n=4) exhibit a transient improvement in
contraction just like DMSO treated controls (n=5). The natural decline of all tissues was
measured once every 10 minutes for 1 hour. After 1 hour, either DMSO or CytoD 3iiM was
applied to the tissues. The two colored envelopes of each kind grey, blue and red each
represent the 68% and 95% confidence intervals (1 and 2 sigma) of the corresponding data
Fig. 11: C2C12-ChR2[H134R] plasmid schematic
Fig. 12: Effect of CytoD 3 M (30 mins) on change in morphology of C2C12 myotubes grown on
IBIDI-treat dishes. Scalebar is 100um. Also shown is the change in index of movement with
CytoD application, which is a measure of change in local pixel grayscale values with time.
Closer to red is indicative of larger pixel changes, which happens when there are larger
displacements. Closer to blue indicates almost no displacement, indicating areas without any
contraction.
Fig. 13: Effect of CytoD 3 M (30mins) and DMSO on change in active displacements of C2C12
myotubes grown on IBIDI-treat dishes. CytoD treatment dramatically increases the active
displacements of the myotubes, while DMSO treated controls result in only a very mild
increase. The five point star points to the mean values of the displacements, which are also
shown in green below the swarm plot. * p = 0.0045 One-tailed Mann Whitney U-test. ** p <
0.0001 One-tailed Mann Whitney U-test
Fig. 14: Acrylic/kapton base mount for 3D muscle formation and force sensing. The distance
between the faces of the 2 cantilevers is 3mm. Also the entire acrylic base was inserted to fit
snugly in a regular 35mm petri dish.
Fig. 15: Sequential process for the fabrication of a 3D muscle bundle attached to a compliant
and a rigid cantilever, for measurement of optically stimulated contractile force. Process
adapted from the sacrificial molding process described elsewhere1
Fig. 16: Phase contrast images of the development of the muscle fiber bundle. The
myoblast/ECM gel compacts soon after cell seeding and compacts successively over the course
of the differentiation. In this case, the culture was switched to differentiation medium 2 days
after cell seeding and the final assay (force, stiffness etc.) was conducted on day 12 after
switching.
Fig. 17: Image processing pipeline to detect (A) cantilever active movement. (B) A typical
pipeline is shown with the final output of the algorithm being the position of the edge of the
cantilever as shown in red overlaid on top of the raw image. The green lines are many lines
output by the Hough transform algorithm which detects many lines along the cantilever edge.
A linear regression is then performed to estimate a single edge based on all these edged
(shown in red). The position of this cantilever is tracked over time to estimate the
displacement (both the x-location and slope of the line are considered).
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Fig. 17: Image processing pipeline to detect cantilever active movement. A typical pipeline is
shown with the final output of the algorithm being the position of the edge of the cantilever as
shown in red overlaid on top of the raw image. The green lines are many lines output by the
Hough transform algorithm which detects many lines along the cantilever edge. A linear
regression is then performed to estimate a single edge based on all these edged (shown in red).
The position of this cantilever is tracked over time to estimate the displacement (both the x-
location and slope of the line are considered).
Fig. 18: Timecourse of active contraction of C2C12 based 3D muscle tissues. The contractility
seems to saturate (or change slower) after day 8 and peak contraction is reached between day
8-12. The two colored envelopes represent the 68% and 95% confidence intervals. n = 10
independent muscle fibers were used for this experiment. The contractility of each muscle
fiber was normalized with respect to its respective maximum during the timecourse of
differentiation.
Fig. 19: Timecourse of active contraction changes of C2C12 based 3D muscle tissues, within 3
hours. Statistically significant differences (p < 0.05) between the CytoD (n=5) and the DMSO
(n=5) are observed as early as 15 minutes
Fig. 20 Dose response test of 3D muscle active contractility with Cytochalasin D. The
contractions are measure prior to treatment (Pre-Treatment) as well as 2 hours after CytoD or
DMSO treatment. Normalization is with respect to the contraction prior to treatment. In the
case of Blebbistatin, treatment with 50ptM of this myosin inhibitor completely nullified the
active force within 5 minutes of treatment. ** One-tailed Mann-Whitney test p = 0.00539. NS, p
> 0.05 One-tailed Mann-Whitney test. * p = 0.0105 One-tailed Mann-Whitney U-test
Fig. 21 Dose response test of 3D muscle active contractility with Latrunculin A. The
contractions are measure prior to treatment (Pre-Treatment) as well as 2 hours after LatA or
DMS0 treatment. Normalization is with respect to the contraction prior to treatment.
Fig. 22 Caspase-3 mRNA quantification (n=3) after 2 hours of CytoD 0.3ptM or DMSO
treatment. p = 0.37. A one-tailed 2-sample t-test was used for statistical significance testing.
Fig. 23 Cell viability changes (n=6) after 52 hours of CytoD 0.3iiM or DMSO treatment. p = 0.46
A one-tailed 2-sample t-test was used for statistical significance testing.
Fig. 24 CytoD treatment likely leaves the plasma membrane intact. It does not significantly
change the activity of Creatine Kinase in the supernatant of the optically stimulated C2C12
myotubes relative to DMSO treated and optically stimulated controls. However, as expected for
positive controls, Triton 0.1% treated samples as expected, show a significant 4-fold increase
in CK activity relative to DMSO controls, indicating the presence of CK in the cells. A one-tailed
2-sample t-test was used for statistical significance testing. p = 0.16 NS for CytoD (n=6) vs
DMSO(n=6). p = 7.5*10- for Triton (n=3) vs DMSO(n=6)
Fig. 25 Effect of a fatigue loading optical stimulus on muscle active contractility with (or
without) f-actin disruption using CytoD (or DMSO). DMSO controls show a self-strengthening
behavior after 15minutes of fatigue load, while CytoD treated tissues do not. A one-tailed Mann
12
Whitney U-test was used for statistical significance testing. NS (p>0.05). *(p=0.032). N=3
samples were used for each condition.
Fig. 26 F-actin disruption with CytoD does not affect autophagy as indicated by the CytoID
fluorescent based assay. N=3 samples were used for each condition. A 2-sample one-tailed t-
test was used for statistical significance testing.
Fig. 27 The DMSO control tissues don't show any significant change in active muscle
contractility. Shown are the effects of DMSO application to C2C12 skeletal muscle active
contractility 2 hours after treatment, 1 day after treatment, as well as 1 day after washout
(which is 2 days after the treatment was initiated). The active force measured at different
times for each device are normalized to the corresponding pre-treatment force (n=5).
Statistical significance tests were conducted using a paired one-tailed t-test to check if any
potential increases are significant.
Fig. 28 Mild f-actin disruption with CytoD 0.3[iM shows a significant increase in active muscle
contractility within 2 hours (1.6X) and a smaller (but not statistically significant) increase a
day after treatment. The plot shown is the effect of CytoD 0.3kM application to C2C12 skeletal
muscle active contractility 2 hours after treatment, 1 day after treatment, as well as 1 day after
washout (which is 2 days after the treatment was initiated). The active force measured at
different times for each device are normalized to the corresponding pre-treatment force (n=7).
Statistical significance tests were conducted using a paired one-tailed t-test to check if any
potential increases are significant. There is a statistically significant drop in active contraction
1 day after washout of CytoD 0.3[iM indicating at least partial reversibility of CytoD's effect,
partial because the force is still 50% greater than force prior to treatment (statistically
significant).
Fig. 29 Strong f-actin disruption with Cyto 3iiM shows a significant increase in active muscle
contractility within 2 hours (2.6X), a deleterious decrease relative to the peak of nearly 50%
down to 1.4X and a recovery to nearly the level of the 2 hour peak (2.3X) within a day of CytoD
washout. The plot shown is the effect of Cyto 3 M application to C2C12 skeletal muscle active
contractility 2 hours after treatment, 1 day after treatment, as well as 1 day after washout
(which is 2 days after the treatment was initiated). The active force measured at different
times for each device are normalized to the corresponding pre-treatment force (n=10).
Statistical significance tests were conducted using a paired one-tailed t-test to check if any
potential increases are significant. There is a statistically significant drop in active contraction
1 day after washout of Cytod 0.3 M indicating at least partial reversibility of CytoD's effect,
partial because the force is still 50% greater than force prior to treatment (statistically
significant).
Fig. 30 Comparison of the effect of CytoD for longer term (2hrs to 2 days) on muscle
contractility relative to the forces during muscle differentiation. In the case of CytoD 3kM and
DMSO, a 2 hour pulse was applied and then washed out to test the recovery and reversibility
long term. This was compared with a continuous mild f-actin disruption with CytoD 0.3kM for
13
days. Clearly, both the high dose (3 M) pulse of CytoD and the low dose continuoud treatment
both led to sustainable improvement in active contraction beyond the DMSO pulse control and
relative to the maximum force during differentiation (all fibers were normalized with respect
to their respective peaks during days 2-12 of differentiation. The colored envelopes around
each means curve (black, blue, green and red) represent 68% and 95% confidence intervals.
Fig. 31 Fluorescence intensity of CytoD EverFluor-TMR measured 2 hours after treatment and
after washout. (A) a phase contrast image showing a typical 3D muscle fiber. (B) The first row
of images contains the raw images used for quantification purposes in Fig. 32. The second row
contains histogram normalized versions of images in the first row. The normalization with
respect to the 2 day washout image in order to make the visibility of the muscle fiber clear,
while still maintaining the relative intensity. Clearly there is a significant drop in intensity,
almost imperceptible by 1 or 2 days after washout. Scalebar 300[im
Fig. 32 Fluorescence intensity of CytoD EverFluor-TMR measured 2 hours after treatment and
after washout. All the intensities were normalized between 0 and 1 with respect to the
maximum average intensity measured as well as the minimum (throughout the experiment).
The background intensity could vary from day to day, due to changes in environmental
conditions as well as variations in the laser. So the intensity values corresponding to zero
CytoD concentration are - 6*10-4 for both the pre-treatment and 2 hour cases. In the 2 hour
image, the background is high because it contain CytoD-EverFluor. However, the intensity of
the muscle fiber is even higher than that as it seems that CytoD reacts with f-actin and
accumulates inside the muscle. 2 hours after treatment, the average intensity on the muscle
fiber is -1000-fold larger than the pre-treatment background. One day 1 after washout, the
muscle intensity drops to being 5-fold larger than background (-200-fold reduction) and on
day 2, it drops to being 1.4-fold larger than background (i.e. a -700-fold reduction compared
to the 2 hour peak)
Fig. 33: Diffusion of Cytochalasin D - Everfluor conjugate through a muscle fiber. (A) Confocal
fluorescence timelapse images of the Cytochalasin D - Everfluor conjugate penetrating the 3D
muscle tissue. Scale bar in images is 100im. (B) Quantification of the fluorescence intensity
variation, with time. All intensities are normalized with respect to the same maximum 16-bit
greyscale spectrum. Every line at any given time point represents the average intensity across
the muscle fiber averaged over 30 cross sections along the length of the muscle.. 3 of the cross
sections are shown in the first image in (A).
Fig. 34: Visualization of f-actin in mature and immature myotubes using Sir-Actin and confocal
timelapse microscopy reveals that sarcomeric f-actin in mature myotubes is not
depolymerized by CytoD 0.3ptM. However, a small fraction of the non-sarcomeric f-actin is
depolymerized with CytoD. For instance, in window 2: the arrows mark areas with f-actin
clustering at T=30 and 150mins(dark rounded spots), which is typical when filamentous actin
breakdown appears (also see Fig. 36B for more obvious clustering). Also shown using arrows
in window2 (between T=60 and 90mins) as well as in window 3 (T= 90mins) is the sudden
appearance of a lighter background, indicating the disappearance of the dark f-actin. Scalebar
is 10pm.
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Fig. 35: Visualization of f-actin (Sir-Actin) in mature sarcomeric myotubes with CytoD 0.3 IM
application using confocal timelapse microscopy reveals that while sarcomeric f-actin in
mature myotubes are not depolymerized by CytoD 0.3pM, the non-sarcomeric non-specific f-
actin (darker) around the periodic f-actin structures do get depolymerized. This is also
illustrated in the intensity line plot showing that the periodic structures remain after 12 hours,
while the overall intensity level comes down, due to depolymerization of some of the non-
specific, non-periodic background f-actin. The scalebar is 10 m.
Fig. 36: Visualization of f-actin (Sir-Actin) in immature sarcomeric myotubes as well as
immature non-sarcomeric myotubes with CytoD 0.3[.M application using confocal timelapse
microscopy reveals that (A) Even the period sarcomeric f-actin gets disrupted if the myotube
organization is immature as seen in A with the imperfectly aligned developing sarcomeric
structure. (B) Several f-actin filaments in the non-sarcomeric immature myotubes are severed.
There is also a lot of f-actin clustering (all within 2 hours). Scalebar is 10pm.
Fig. 37: (A) Quantification of the non-sarcomeric stress-fiber like f-actin breakdown in pre-
sarcomeric immature myotubes shows that the distribution of linear f-actin filaments gets
skewed towards shorter filaments with CytoD treatment (B) There seem to be many more
stress-fiber like f-actin filaments with CytoD treatment. i.e. CytoD treatment converts a few
long f-actin filaments into many more shorter filaments. (C) Quantification is performed by
manually counting stress-fiber like f-actin structures and measuring their length using the
length tool of ImageJ software. An example of an stress-fiber like actin filament in shown with
a red curly brace showing the extent of the filamentous. The beginning and ends were chosen
(subjectively) based on the location where there appears to be a branching of the bundled
stress-fiber like f-actin or a clear stop.
Fig. 38: Schematic of fluorescence recovery after photobleaching of GFP-tagged actin
monomers. Monomer recovery occurs first and is the most rapid (GFP-tagged monomers
indicated by the green blobs and the background green used to doubly emphasize the location
of unbleached GFP-tagged monomers). F-actin turnover driven recovery is slower than the
diffusion of monomers (10X slower), and so can be considered to occur after monomer
recovery is complete. This is schematically indicated by the grey (bleached) f-actin filaments
acquiring some green blobs (unbleached monomers) from the barbed/polymerizing end of f-
actin. Some of the bleached f-actin filaments recover much more slowly (10s of minutes) due to
protective capping proteins. These are schematically shown to never recover (always grey
after bleaching) in the timescale of the experiments conducted (2-3 minutes).
Fig. 39: A typical FRAP recovery curve and pictures from actual experiments. C2C12 myotubes
with GFP-actin monomers are bleached with a rectangular window covering the entire width
of the cell throughout the entire depth. Scalebar is 10im. By plotting the intensity recover
within the bleach window over time and by using the remaining image to compute the rate of
photobleaching we obtain a corrected recovery curve, which has a rapid diffusion limited
recovery in the -1s timescale followed by a slower turnover limited recovery.
Fig. 40: The first few seconds of the FRAP recovery curve, plotted based on 19 individual FRAP
experiments conducted at different regions along 3 different myotubes. The rapid initial rise is
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driven purely by diffusion of monomers. We use this recovery profile to compute the
timescale of diffusion and estimate the diffusion coefficient (shown in the inset).
Fig. 41: Relative change ratio of the fractions of the various actin compartments (actin
monomer, dynamic f-actin and stable f-actin). The Y-axis represents the ratio of (Dynamic F-
actin fraction after treatment)/(Dynamic F-actin fraction before treatment) etc for the various
compartments (Dynamic, stable F-actin as well as Monomeric actin). The various treatment
conditions (DMSO, CytoD) are shown in shades of green. The red dots represent the mean
values. * p = 0.029 with a one-tailed unpaired 2-sample t-test with respect to the DMSO
controls. N=5 was used for DMSO and CytoD 3IiM conditions. N = 9 was used for the CytoD
0.3pM condition.
Fig. 42: Relative change ratio of the timescales of dynamic f-actin turnover with the various
treatments. Significance tests were 1-tailed t-tests. The turnover time change with CytoD
0.3 [M is barely statistically significant, while the change due to CytoD 3[IM is highly
statistically significant relative to the DMSO treated controls. A one-tailed unpaired 2-sample t-
test with respect to the DMSO controls. N=5 was used for DMSO and CytoD 3[tM conditions. N =
9 was used for the CytoD 0.3 [M condition.
Fig.43: Treatment with 100 [M SMIFH2, a small molecule inhibitor of formin homology domain
2 improves active skeletal muscle contractility within 2 hours of treatment. This is likely due to
inhibition of the FH2 domain of formins which leads to disruption of formin associated f-actin
filaments and/or inhibition of formation of such filaments as formin is an f-actin nucleator. At
SMIFH2 doses of 20pM or lower, no improvement in contraction was observed. Statistical
significance testing was performed with a one-tailed unpaired 2-sample t-test with respect to
the DMSO controls.
Fig.44: Treatment with CK666 100[tM, an inhibitor of the Arp2/3 complex leads to a gradual
decline of contractility. The data for the change in contraction 2 hours (not-significant) and 1
day (statistically significant) after treatment with CK666 100pM are shown. This makes it
plausible that the branched Arp2/3 mediated f-actin filaments do help in sarcomeric force
transmission. At SMIFH2 doses of 20p.M or lower, no statistically significant change in
contraction was observed after 2 hours (shown) of contraction or after 1 day (not shown).
Statistical significance testing was performed with a one-tailed unpaired 2-sample t-test with
respect to the DMSO controls.
Fig. 45: Treatment with TR100, an anti-tropomyosin compound targeting the non-sarcomeric
tropomyosin isoform Tpm3.1 leads to a decline in muscle contractility 2 hours after treatment.
Statistical significance testing was performed with a one-tailed unpaired 2-sample t-test with
respect to the DMSO controls.
Fig. 46: Treatment with ATM3507, another anti-tropomyosin compound targeting the non-
sarcomeric tropomyosin isoform Tpm3.1 leads to a decline in muscle contractility 2 hours
after treatment. Statistical significance testing was performed with a one-tailed unpaired 2-
sample t-test with respect to the DMSO controls.
Fig. 47: Gene expression analysis using RT-PCR for 21 genes including housekeeping gene 18s
rRNA, with CytoD 0.3pM application for 2 hours. The relative expression levels are colored
with a log2 scale (10-3 to 103). No significant changes in gene expression were found. There
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were 3 samples used for both CytoD and the control (DMSO), labeled 1-3. A 2 sample t-test was
used to obtain significance levels of the relative expression, with samples made in triplicate.
Fig. 48: AFM indentation of C2C12-based myotubes reveals a drop in mechanical stiffness. (A)
AFM approach retraction curve (red) with a curve-fit (green) to the approach curve. A Hertz
model was fit to the data to compute the apparent elastic modulus. (B) CytoD treatment clearly
lowers the apparent elastic modulus relative to DMSO treated controls (AFM) by 50%. N=30
cell indentations were used for this test.
Fig. 49: Micro-tensile testing of a muscle tissue. (A) The setup used for testing of the axial
stiffness of a muscle tissue. The typical muscle tissue used in this study is -100lm in diameter,
3mm in length anchored between two clamped kapton cantilevers (orange in color), one
relatively compliant and the other relatively rigid (as described earlier in Chapter 2). The setup
allows simultaneous measurement of the active contraction by observing the movement of the
compliant cantilever (see the text in Sec. 4.2.2). Furthermore, the slidable rigid cantilever
allows the muscle to be stretched and relaxed by 50 [tm steps, which also allows estimation of
the axial stiffness. For a sense of scale, the circular tissue mount fixture is -6cm in diameter.
The distance between the cantilevers in the fixture is 3mm. (B) The image processing pipeline
used for stiffness computation. The first image represents the raw image of the initial position
of the compliant cantilever edge. The second image represents difference image between the
initial and final positions of the compliant cantilever as the rigid cantilever is moved to stretch
the muscle tissue. The thickness of the bright rectangular zone is the displacement. An edge
detection algorithm similar to the one described in Chapter 2 (see appendix 2) is used to detect
the two edges of the bright strip. (C) Shows the cantilever position displacement (black), the
cantilever displacement (red) and the normalized stiffness (blue).
Fig. 50: CytoD treatment leads to a simultaneous decrease in axial tissue stiffness and
improvement in active contraction as measured by the micro-tensile testing assay. The
timescale of the 2 changes match each other well. (n=5) was used for this experiment.
Fig. 51: CytoD (0.3 M) treatment does not significantly change the baseline glucose
consumption rate of the differentiated C2C12 cells. A 1-tailed 2 sample t-test was used for
statistical significance testing.
Fig. 52: CytoD treatment (0.3[tM or 3pM) for 2 hours does not significantly change the
phosphorylation of AKT at the 2 phosphorylation sites (Ser473 and Thr308). A) Western blots
showing pAKT expression levels for both sites Ser473 and Thr308 along with AKT as a
function of CytoD concentration. P-tubulin and p-actin are also shown as loading controls B)
Averaged results showing the ratio of phosphorylated AKT to total AKT. A 2-sample 1-tailed t-
test was used for statistical significance testing (p > 0.05). N=3 for all experiments.
Fig. 53: CytoD treatment (0.3ptM or 3[tM) does not significantly change cellular metabolic
activity as assessed by an MTT assay. See text for details about the time of exposure. A 2-
sample 1-tailed t-test was used for statistical significance testing (p > 0.05). N=4 was used for
these experiments.
Fig. 54: CytoD treatment does not significantly change mitochondrial activity as assessed by no
significant changes in accumulation of TMRE a fluorescent dye that accumulates only in active
mitochondria. A 2-sample 1-tailed t-test was used for statistical significance testing NS (p >
0.05). N=3 was used for these experiments.
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Fig. 55: Mechanical basis of active force improvement due to f-actin disruption in skeletal
muscle.
Fig. 56: Jasplakinolide 5[iM treatment decreases active contractility of C2C12 based 3D
engineered muscle by 25% within 2 hours of exposure and 33% within 24 hours of exposure.
Statistical significance testing is based on the 1-tailed 2 sample t-test
Fig. 57: Phalloidin 100ptM treatment decreases active contractility of C2C12 based 3D
engineered muscle by 25% within 24 hours of exposure. 2 hours after treatment, there was no
significant change in contractility relative to DMSO treated controls. Statistical significance
testing is based on the 1-tailed 2 sample t-test
Fig. 58: Biobot fabrication process involving 3D printed hydrogel molds, molding optogenetic
skeletal muscle and assembly of the bio-hybrid structure.
Fig. 59: CytoD treatment increases the twitch length of a weak biobot and this improvement
also results in translation of the biobot (which was so weak prior to treatment that it didn't
exhibit net translation upon optogenetic stimulation). The yellow lines are fixed and were




We live in historic times due to advances in modern medicine. The discovery of
antibiotics and vaccines has eradicated many fatal infectious diseases and widespread access
to the modern healthcare infrastructure is transforming our lives. A byproduct of this
transformation is that we live longer today than ever before; we live in an aging world. The
population of people aged 60+ is increasing each year, with an expected 100M+ Americans
aged 60+ expected by 2050 (Fig. 0). The unfortunate side effect of this aging demographic is
the increase in age-associated diseases and disorders. Such disorders include age-related
neurological diseases such Alzheimer's and Parkinson's disease, age-related visual disorders
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Fig. 0: US population demographics aged 60+ (U.S. Bureau of the Census)
Sarcopenia is a skeletal muscular disorder characterized by decline in skeletal muscle
mass and strength of muscle function. It is part of the so-called frailty syndrome, which is
characterized by excessive decline in one's health worse than what is expected due to normal
aging. Decline in muscle mass and strength leads to increased weakness and decreasing
mobility for performing the same daily tasks. This leads the typical patient to exert themselves
19
less and less. Such lack of activity further worsens muscle function which worsens mobility
even more. This vicious cycle of loss of muscle function in Sarcopenia is surprisingly common,
thought to affect 1 in 4 people aged 65+.
1.2 Strategies to combat declining muscle function
Efforts combating declining muscle function could be characterized in to two types:
pharmacological or non-pharmacological. Non-pharmacologically, exercise and resistance
training have been shown to demonstrably improve muscle function 2-27. However, this doesn't
stop the vicious cycle of muscle loss without significant self-motivation. Pharmacologically,
there have been several targeted attempts at improving muscle function. Muscle function is
driven by muscle mass and muscle contractility per unit mass.
The vast majority of pharmacological strategies today target improvement of muscle mass
(eg. see Fig. 1) . Examples include anabolic steroids that have been shown to increase muscle
hypertrophy as well as formation of new muscle fibers partially through the activation of
satellite cells. Landmark discoveries 28,29 about the role of the AKT/mTOR pathway in
increasing muscle hypertrophy has opened up a whole decade of research 28-47 dedicated to
understanding this mechanism.
Likewise, inhibiting myostatin 48-71 decreases protein breakdown and increases muscle
mass as a result (Fig. 1).. All the above modalities have received significant attention both from
academia and commercial entities pursuing therapeutic programs based on them. However,
there is a lack of pharmacological interventions directly targeting the improvement of muscle
contractility. Intr
Muscle contractility per unit area is driven by the intrinsic strength of the muscle fibers as
well as the effectiveness of neuro muscular coupling which may change the fraction of
activated muscle fibers at any given time. Both of these targets have received relatively little
attention from a pharmacological standpoint. In this study, we focus on the intrinsic strength
of muscle fibers and explore strategies to improve this metric.
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Fig.1. Cow with defective myostatin gene, as well as myostatin knockout mice displaying
increased muscle mass 72
1.3 Thesis direction and outline
Even decades after Huxley's Nobel prize winning discovery of acto-myosin sliding
contraction 73 ,74 in striated muscle, we still don't completely understand how the acto-myosin
force transmits from the sarcomeres to perform external work. We hypothesize that the non-
sarcomeric cytoskeleton (f-actin structures that are not part of the sarcomeric f-actin,
intermediate filaments and microtubules) plays a significant role in muscle force transmission.
This is plausible because these 3 cytoskeletal structures are the usual load bearing networks
within cells.
Among these 3 structures, it is likely that the non-sarcomeric f-actin is especially important
as a mechanical link that helps in force transmission because of the known f-actin binding sites
on the Z-disk of the sarcomeres, on dystrophin and in the integrin complex 75(Fig. 2A).
Furthermore, the sarcomeric acto-myosin cytoskeleton follows an exquisite periodic structure
that is intact even in the mechanically active environment of skeletal muscle. This leads to the
hypothesis that there may be cytoskeletal structures (beyond the titin molecule that runs
along each sarcomeric unit), that scaffold the sarcomeres holding them in place. If the non-
sarcomeric f-actin is involved in either of these 2 roles (force transmission or sarcomeric
scaffolding), it is likely that disrupting f-actin would be deleterious to muscle force
transmission.
On the other hand, it is known that f-actin adds rigidity to cells. So the very presence of
non-sarcomeric f-actin may impede contraction according to the Hill model of muscle
contraction (Fig. 2B), due to the additional parallel resistance. Based on this purely
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Fig.2: The unclear role of the non-sarcomeric f-actin in skeletal muscle force transmission. (A)
Figure from 7s. Protein binding studies have led to the hypothesis that f-actin links the
sarcomeres to the costameres (which are the sites of connection of myotubes to extracellular
sites). If this f-actin link is critical, disrupting non-sarcomeric f-actin may negatively affect
force transmission. (B) Alternatively the non-sarcomeric f-actin may make the cell more rigid
mechanically impeding contraction. In the Hill muscle model shown, the non-sarcomeric f-
actin may contribute additional mechanical resistance to the parallel element, thereby
mechanically posing an additional barrier to muscle contraction. In this case, disrupting the
non-sarcomeric f-actin may enhance muscle contraction.
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So there are 2 alternate hypotheses for the role of the non-sarcomeric f-actin:
1. Disrupting non-sarcomeric f-actin is deleterious to muscle force transmission due to
interference with the ability of the sarcomere-generated force to be transmitted to external
structures.
2. Disrupting non-sarcomeric f-actin enhances muscle force transmission since in normal
muscle it acts to constrain contraction, acting against the muscle.
Surprisingly, to-date there is very little evidence that would conclusively support one
hypothesis over another. The goal of this thesis is to elucidate the role of the non-sarcomeric f-
actin to answer the question: Is the non-sarcomeric f-actin beneficial to contraction, or does it
biomechanically impede contraction?
The thesis is organized as follows:
In Chapter 2, we develop an ex vivo murine skeletal muscle model and measure the
contractile response of the tissue to actin disruption with Cytochalasin D. If the presence of f-
actin helps force transmission, we expect the disruption of f-actin to have a significant
deleterious effect on the muscle function. On the contrary, CytoD treatment of the explant
reveals two distinct phenotypes, one of which shows a 2-fold improvement in muscle
contractility, until the muscle stops contracting due to rigor mortis hours later. In order to
verify if this phenotype of functional improvement due to actin disruption is a real biological
phenomenon or merely artifactual, we need a more stable muscle model that doesn't undergo
rigor mortis.
To overcome the shortcomings of the ex vivo model, we use an in vitro muscle model using
optogenetically engineered skeletal myoblasts. This model doesn't undergo rigor mortis and is
stable for days after peak differentiation, during which time we may perform detailed actin
disruption experiments. Furthermore the optogenetic activation of muscle contraction helps
decouple neuro-muscular coupling from the intrinsic muscle strength. With a 2D differentiated
myotube model, we show that the active displacements of the myotubes improve almost 15-
fold after actin disruption with CytoD. However, this apparent functional improvement could
be due to weaker cell substrate adhesions that occur during actin disruption.
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In order to rule out this possibility and to test if increased active displacements translate to
increased active forces, we developed a 3D engineered mouse muscle in vitro model. This
model has a muscle tissue cast on flexible supports and differentiated in situ. The displacement
of the supports provides a measure of the active contractile force. Even the 3D engineered
model shows a dramatic 2-fold improvement in contractile force with actin disruption with
CytoD. Furthermore, we show that Latrunculin A treatment also leads to a similar level of
improvement in contractility showing that f-actin disruption underlies the force improvement,
not other non-specific pleiotropic effects of CytoD.
This counterintuitive functional improvement due to actin disruption led us to consider
potential downsides of actin disruption. We tested if there are changes in apoptosis, cell death,
mechanical integrity of the cell under an exercising stimulus, intracellular protein/organelle
damage and fatigue resistance. The assays show almost no downside, with no detectable
changes in apoptosis, cell death, autophagy or mechanical integrity with mild f-actin
disruption. The only potential functional downside we have uncovered so far is a small
decrease in fatigue resistance. This is indeed promising and very surprising that f-actin
disruption, which is typically thought to have negative functional consequences, shows such a
positive functional improvement in active force in skeletal muscle, with seemingly very few
measured tradeoffs.
In Chapter 3, we perform experiments that pinpoint the dynamics of the cytoskeletal
changes underlying the observed functional improvement. Using a dose response of the force
to Cytochalasin D and the force recovery after washout, we hypothesize that both dynamic f-
actin components as well as some of the stable actin must be disrupted. Longer term exposure
to CytoD still seems beneficial at low doses, leading to the hypothesis that the sarcomeric f-
actin must not be affected by CytoD.
To test these hypotheses, we performed live 3D confocal timelapse microscopy to visualize
changes in f-actin structure using low doses (100nM) of a fluorogenic small molecule that
binds to f-actin. These experiments reveal that Cytochalasin D disrupts the non-specific f-actin
structures and long f-actin cables, while leaving the sarcomeric f-actin structures remain
intact, agreeing with our earlier hypothesis. Presumably some of these well-defined f-actin
cables do not recover soon after washout and this explains the irreversible improvement in
contraction even after complete CytoD washout.
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Furthermore, we also performed a fluorescence recovery after photobleaching (FRAP)
assay to study f-actin dynamics in further detail. GFP-tagged actin monomers were transfected
in to differentiated myotubes and a FRAP assay conducted. The FRAP assay revealed that the
speed of f-actin turnover slows down with increasing doses of CytoD, implying that dynamic f-
actin filaments that have fast turnover increasingly get disrupted with increasing doses of
CytoD. This confirms our hypothesis that dynamic f-actin is getting disrupted.
To further narrow down the specific sub-compartments of f-actin that lead to functional
improvement, we tested the changed in contractility with more specific actin inhibitors. As a
result we found that disruption of formin mediated actin assembly also improves muscle
contraction. The commonality between the CytoD treatment and formin inhibition is the
disruption of several f-actin filaments leading to shorter filaments.. On the other hand,
disrupting Arp2/3 mediated branched actin or f-actin filaments stabilized by tropomyosin
seems to have a deleterious effect on muscle contraction, implying an essential functional role
of these specific f-actin subtypes in sarcomeric force transmission.
In Chapter 4, we analyze the mechanistic underpinning of the force improvement. We test
a mechanical hypothesis that the force improvement is due to a drop in internal mechanical
resistance of the cell. To test the hypothesis, we performed experiments that capture changes
in internal mechanical resistance (AFM, micro-tensile testing) as well as changes in the
energetic activity of the cell. This is because, for the output contractility of a "motor" such as
the muscle tissue to increase, either the input (energetic consumption) increases, energetic
metabolism changes, or the efficiency of force transmission changes due to a lower internal
resistance. We find that there is no significant change in energetic consumption (glucose),
mitochondrial TCA cycle enzymatic activity (MTT) or mitochondrial activity (TMRE). There are
no significant changes in a range of genes involved in energy metabolism as well as sarcomeric
protein activity, pointing towards mechanical resistance changes as a likely candidate. Both the
AFM and micro-tensile testing reveal a 50% drop in mechanical stiffness. This was to be
expected as f-actin is known to have a structural role in most cells. It's just that in skeletal
muscle, it seems to be over-expressed impeding its contraction. We also tested if f-actin
stabilization which would potentially lead to increased internal resistances decreases force,
and indeed it does. All of the above data point towards a mechanical effect that leads to
functional improvement in skeletal muscle.
25
In Chapter 5, we explore practical applications of f-actin disruption and propose several
future studies. The preceding sections show that the twitch force improves with f-actin
disruption. Here we discuss the practical significance of this. We explore a model of walking
using a 3D printed biohybrid skeletal muscle powered robot and demonstrated significant
improvement in the functional performance of the bio-bot due to f-actin disruption. Future
studies could be directed towards 1) testing f-actin disruption in muscle disease models 2)
developing drug delivery systems and 3) discovering better targets for f-actin disruption.
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Chapter 2: Effect of f-actin disruption on skeletal muscle
function
2.1 Actin disruption in an ex vivo mouse muscle
2.1.2 Does f-actin disruption enhance muscle contraction ex vivo?
In this thesis, we primarily explore the role of the actin cytoskeleton on the functional output
of skeletal muscle, namely active force transmission. As a model system, we start with an ex
vivo mouse muscle to study this. To re-iterate the two alternative theories discussed in the
previous chapter (Sec. 1.3), it is unclear if disrupting f-actin might improve skeletal muscle
contraction (if f-actin mechanically impedes contraction) or worsen it (if f-actin has an
essential function in skeletal muscle cells, perhaps in linking the sarcomeres to the ECM)? In
this section, we experimentally measure the change in contraction due to f-actin disruption to
test these two theories.
2.1.3 Experimental model
2.1.3.1 Tissue dissection
We measure the change in muscle function in a mouse hindlimb extensor digitorum longus
(EDL) muscle explant model due to f-actin disruption using Cytochalasin D (CytoD). Our
rationale for choosing the EDL explant model is as follows:
The mouse EDL muscle explant model is an appropriate model for 3 reasons: 1) mouse
hindlimb muscles have been used for several studies of human muscle disorders 76-83 2)
mature muscle tissues such as this are more appropriate to test our hypothesis that dynamic f-
actin may not be essential for mature skeletal muscle tissue function than using in vitro
engineered muscle models which are still developing tissues 3) EDL muscles are structurally
convenient to test this hypothesis. Being thinner than other muscle tissues (the tibialis
anterior or soleus muscle tissues), we hypothesize that EDL tissues may be more viable after
dissection than much thicker muscle tissues such as the tibialis anterior or soleus muscles.
Furthermore, small molecule actin disrupters such as CytoD may diffuse through the EDL
muscle tissue more completely in shorter timescales than thicker alternatives. Furthermore, it
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has well-defined and intact tendons at both of the ends, permitting easier handling and
anchoring without damaging the muscle fiber belly.
All muscles in this study were harvested from 2-3 month old male C57BL/6 mice which
were sacrificed for an unrelated study and obtained with approval from the MIT Committee on
Animal Care. First, skin was removed from both hind limbs to expose the hind limb muscles
and fascia was removed from over the tibialis anterior (TA) muscle (Fig. 3). The distal TA
tendon was cut and then pulled to peel the TA muscle from the limb. The TA muscle was
carefully dissected at its proximal attachment and discarded. Sterile gauze was used to absorb
excess bleeding caused by the rupture of vessels in the TA muscle. The distal EDL tendon was
then cut with microscissors and then pulled gently to peel the EDL muscle from the limb. An
incision was made in the distal portion of the biceps femoris muscle to expose the proximal
extensor digitorum longus (EDL) tendon and subsequently the proximal EDL tendon was cut
with microscissors. The EDL muscle with associated tendons was then removed from the hind
limb (Fig. 4) and submerged in an isotonic medium (DMEM + 10% FBS + 1%PS) cooled on ice
until functional assays were performed. These muscle explants are viable up to 12 hours after
dissection if kept in ice. If at room temperature or 37C, the explant rapidly undergoes rigor
mortis within 3-4 hours and does not contract any further.
Fig. 3: Euthanized 2-3 month old wild type male mouse with skin removed ready for muscle






Fig. 4: EDL Muscle dissection from the hindlimb. (A-E): Sequential steps of dissection involving
removing the tibialis anterior muscle as well as isolating the EDL muscle from the rest of the
muscle belly. (F): dissection of the proximal tendon of the EDL muscle.
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2.1.3.2 Contractility measurement
We designed a setup to mount the EDL muscle explants on flexible cantilevers with kapton
cantilevers (8N/m stiffness) as supports. The features of the setup being the ability to mount
an EDL muscle on the cantilever, with in built electrodes for electrical stimulation of the




Fig. 5: Tissue mount for the EDL muscle explant with adjustable length and built-in
electrodes for electrical stimulation. (A and B) The CAD models show the top (A) and bottom
(B) of the assembly respectively, with the slidable anchor that is used to adjust the resting
length of the muscle. (C) Kapton based cantilevers are held together with an acrylic-silicone-
acrylic sandwich and inserted in to the rectangular through-holes of the anchor. Furthermore,
an EDL muscle tissue is bonded to the cantilever anchors as shown (D) An Arduino and motor
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Fig. 6: Overall EDL muscle explant assembly connected to a circuit for electrical
stimulation. (A) Zoomed-out view of the tissue mount with the EDL muscle connected to the
micromanipulator for length adjustment. (B) Zoomed-in view showing the mounted EDL
muscle with platinum wire electrodes on either side of the muscle
A drop of cyanoacrylate (quick dry super glue) was applied to the tip of the kapton
supports and was allowed to partially set for 30s. At this point, the EDL muscle explant that
was stored in ice cooled medium, was held with a pair of precision tweezers, primarily held by
the tendons so that damage to the muscle belly was minimized. Then we carefully attached the
tendons to the supports and held it in place for 30 more seconds to fully set. At this point,
warm medium 37C was added to the explants quickly so that they do not dry out. The explant
was incubated in this medium for 10 minutes without any electrical stimulation to wait for the
tissue to warm up. The electrical stimulation setup was ready, connected to a 15V power
supply that can provide an electric field of 15V/cm across the muscle tissue. The electrical
stimulation parameters were 30Hz pulses with pulse width of 5ms, which led to a twitch of the
muscle. A tetanic stimulus (>=10OHz) was not applied in order to delay fatigue and rigor
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Tissue mount
mortis of the muscle tissue for as long as possible. This was necessary as the explant is
expected to undergo rigor mortis, not being perfused like when in vivo in the animal.
Furthermore, a direct in vivo testing of CytoD would not be ethical as it is known to have
significant cardiotoxic effects.
2.1.4 Results and Discussion
2.1.4.1 F-actin disruption in ex vivo mouse muscle improves contractility in a
responsive subset of specimens
First, we verified that CytoD treatment does disrupt f-actin in explant tissues. We treated
explant tissues with CytoD 3[tM or DMSO for 1 hour and fixed the tissues. These tissues were
stained with phalloidin to visualize the presence of f-actin. As shown in Fig. 7, it appears that












Fig. 7: CytoD disrupts f-actin in mouse explant muscle tissues. (A) Phalloidin (Alexfluor
647) stained tissues of muscle EDL explants with CytoD 3 M or DMSO for 1 hour reveal that
CytoD does disrupt the f-actin structures as reflected by lower phalloidin intensity under
identical fluorescence microscopy settings. Scalebar is 60im. (B) The intensity changes were
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quantified with respected to the mean DMSO intensity (n=6). The changes are statistically
significant, as analyzed by a one-tailed 2-sample t-test p = 7.59*10-6
At this point, the length of the tissue was adjusted in increments of 100im using the
micromanipulator, with electrical stimulation applied at each length to find the peak
contraction, measured optically via deflection of the kapton supports. The length was fixed at
this point and the electrically stimulated contraction measured every 10 minutes for 60
minutes. As shown in Fig. 8, the explants become less functional with time, perhaps due to the
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Fig. 8: Decline of EDL muscle explant contractility with time, normalized with respect to
the contractility at 60 mins. The two colored envelopes represent the 68% and 95%
confidence intervals (1 and 2 sigma) of the data. The data represents the average and variation
of 14 explant samples.'
At 60 mins, we introduce our intervention, fresh medium containing either 3RM CytoD or
the carrier DMSO, and continue to monitor changes in the muscle function for 2 more hours or
until rigor mortis sets in. While, all the DMSO treated control tissues display a monotonic
decline in muscle function until complete rigor mortis sets in, we noticed 2 qualitatively
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different response phenotypes in the CytoD treated tissues. Roughly 50% of the CytoD tissues
decline in function in a matter similar to that of the DMSO treated tissues (Fig. 9). This makes it
seem like CytoD has no effect on explant tissue contraction. Also, it doesn't seem to accelerate
the decline any further than DMSO treated controls. This implies that either CytoD does not
disrupt any of the actin (this is not true, as shown in Fig. 7), or disrupting f-actin has no effect
on muscle contraction. The later supports neither of the two hypotheses discussed in the
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Fig. 9: About half of the CytoD treated tissues (n=5) decline in contraction just like DMSO
treated controls (n=5). The natural decline of all tissues was measured once every 10 minutes
for 1 hour. After 1 hour, either DMSO or CytoD 3sM was applied to the tissues. The two colored
envelopes of each kind grey, blue and red each represent the 68% and 95% confidence
intervals (1 and 2 sigma) of the corresponding data
However, in the other half of the CytoD treated tissues (Fig.10), we notice a transient
improvement in overall function to -2X the contractility just before treatment followed by a
decline. The average tissue contractility in this set of CytoD treated tissues was statistically
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significantly improved relative to the DMSO treated controls (the mean CytoD curve lies
outside of the 95% envelope of the DMSO treated controls). The response of this set of tissues
supports the hypothesis that f-actin disruption enhances contraction (perhaps due to lowering
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Fig. 10: About half of the CytoD treated tissues (n=4) exhibit a transient improvement in
contraction just like DMSO treated controls (n=5). The natural decline of all tissues was
measured once every 10 minutes for 1 hour. After 1 hour, either DMSO or CytoD 3[ M was
applied to the tissues. The two colored envelopes of each kind grey, blue and red each
represent the 68% and 95% confidence intervals (1 and 2 sigma) of the corresponding data
2.1.4.2 Conclusion and limitations of the explant model
Overall, this experiment shows that f-actin disruption may have a beneficial effect on
skeletal muscle tissue contraction. However, admittedly the explant experiment is not
conclusive due to the variability in response observed, and if all the data are combined, the
increase is still apparent but lacks statistical significance. There could be several sources for
the observed variability: 1) inherent animal to animal, and tissue to tissue variability (we tried
to minimize any potential bias due to this by using both EDL muscles from a given animal for
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CytoD and DMSO respectively). 2) variability in tissue dissection. Tissue dissection has its
inherent variability due to the difficulty of handling and cutting the small EDL muscle from the
mouse hindlimb. Moreover, the epimysium covering the EDL muscle may be damaged to
differing extents which could alter the transport properties of CytoD and the tissue response
3) variability in tissue mounting. This too is variable and may sometimes lead to drying out of
the tissue while mounting.
On top of the variability, the rigor mortis of the tissue is by far the biggest limitation of the
explant experiment. The fact that the tissue is not perfused outside of the animal causes the
rigor mortis shown in Fig. 8. This makes it impossible to study the long term response to f-
actin disruption. A key unanswered question is the following: if rigor mortis was not a concern,
is the functional improvement due to f-actin disruption transient or persistent? Due to the
limited lifetime of explants, we need other methods to test this. To overcome these limitations
of explant-function measurements, we develop an in vitro engineered muscle tissue model by
differentiating mouse myoblasts either in 2D or 3D.
2.2 F-actin disruption in a 2D in vitro model
2.2.1 Hypothesis: F-actin disruption improves 2D myotube contraction
Drawing upon the preliminary findings of the explant experiment, we hypothesize that F-actin
disruption with CytoD improves 2D myotube contraction. We want to create a model that is
stable for the time course of the experiment, does not undergo rigor mortis and test its
response to f-actin disruption.
2.2.2 Experimental model
2.2.2.1 Optogenetic C2C12 2D myotube differentiation
We used the murine myoblast cell line C2C12 (ATCC) and transfected them with a pLenti2-
EFla-ChR2[H134R]-tdTomato-WPRE plasmid to express a mutated variant of the light-
sensitive ion channel, Channelrhodopsin-2(ChR2[H134R]) as shown in Fig. 11. Detailed
protocols are described elsewhere84 . Briefly, cells were transfected with 10 mg of EFla-
ChR2[H134R]-tdTomato, 15mg of psPAX2, 10 mg of pMD2.G, 100 ml of Lipofectamine 2000
(ThermoFisher), and 200 ml of PLUS Reagent (ThermoFisher). Lentiviral packaging plasmids
(psPAX2 and pMD2.G) were a gift from D. Trono (Addgene, plasmid #12260 and #12259).
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C2C12 cells were grown until 70% confluence in a T1i0 flask and re-suspended in a Matrigel
coated (100ug/ml, 1hr at 37C) IBIDI-treat 35mm dish at a density of 500K cells per dish. Cells
were cultured in growth medium (Dulbecco's Modified Eagle Medium (DMEM) supplemented
with 10% fetal bovine serum (FBS), 1% penicillin and streptomycin (PS) until they reached
confluence. At this point, they were switched to myogenic differentiation medium DM,
composed of DMEM supplemented with 4% horse serum (HS), 50 ng/ml mouse insulin-like
growth factor-1 (mIGF-1), 1 mg/ml E-aminocaproic acid (AA) and 1% PS. All cells were
cultured at 37'C with 5% C02 in a humidified incubator.
ChR2HI" plasmid for C2C12
LTR psRRE cPPT pEFla Ch2[I34.RJ tdTomato WPRE LR




Fig. 11: C2C12-ChR2[H134R] plasmid schematic
2.2.2.2 Optogenetic stimulation
At day 12 after introducing differentiation medium, the differentiation of the cells was checked
by exposing the cells to blue light. Optical stimulation was performed using a SOLA light
engine (Lumencor) excitation unit. The blue light emission peak is at 470nm. Blue light was
supplied through Zeiss filter set #38 (BP 470/40). The optical stimulations of the
differentiated myofibers was conducted through a 4x objective, yielding an irradiance of 1.2
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mW mm- 2 , both the highest intensity of the Lumencor engine as well as an intensity higher
than the intensity at which the contraction started to plateau (-0.6mW/mm 2 ). The shutter
was controlled via the TTL port of the Lumencor engine through an Arduino Uno board.
2.2.3 Results and Discussion
2.2.3.1 CytoD increases 2D myotube active contractions 14-fold
Cells were stimulated with blue light pulses (Sms ON, 30Hz) to record the active displacement
prior to CytoD treatment. They were then treated with CytoD 3 IM or DMSO for 30 minutes.
Fig. 12 shows the change in morphology. The change in active displacements was significant
with CytoD as also illustrated in Fig. 12 using an index of movement metric, (I(0.5s)-I(0)),
normalized within each condition, and color mapped between 0 (blue) and 255 (red). The
active displacements were quantified using the ImageJ Mosaic 2D particle tracking plugin by
tracking 200 random points on myotubes in both the DMSO and CytoD treated samples, before
and after treatment. DMSO treated cells showed only a small change in average active
displacements before and after treatment (0.89 to 1.02ptm), while CytoD treated tissues
showed a very significant increase in the contraction, an increase in the average active
displacements of approximately 14-fold from 1.4Iim to 20 Lm (p <0.0001, one-tailed Mann-









Phase image Index of movement
Fig. 12: Effect of CytoD 3iM (30 mins) on change in morphology of C2C12 myotubes grown
on IBIDI-treat dishes. Scalebar is 100um. Also shown is the change in index of movement with
CytoD application, which is a measure of change in local pixel grayscale values with time.
Closer to red is indicative of larger pixel changes, which happens when there are larger


















O.89p~m 1.02pmr 1.38um 20.07pim
I Ia
Fig. 13: Effect of CytoD 3[iM (30mins) and DMSO on change in active displacements of
C2C12 myotubes grown on IBIDI-treat dishes. CytoD treatment dramatically increases the
active displacements of the myotubes, while DMSO treated controls result in only a very mild
increase. The five point star points to the mean values of the displacements, which are also
shown in green below the swarm plot. * p = 0.0045 One-tailed Mann Whitney U-test. ** p <
0.0001 One-tailed Mann Whitney U-test
2.2.3.2 Conclusion and limitations of the 2D myotube model
In conclusion, clearly f-actin disruption using CytoD treatment amplifies the active
displacement significantly. This is yet another surprising result in the context of our general
understanding of the importance of f-actin to cellular function. However, it does partly support
the improved active contractility observed in the ex vivo model.
One of the limitations of this model is that increased active displacements do not necessarily
translate to increased active forces. This is because with CytoD treatment the 2D cell







cell substrate adhesion could explain the increased contractions as the monolayer probably
faces very little resistance from the substrate. In order to control for this factor, and to
measure actual forces, we developed a 3D muscle tissue model.
2.3 F-actin disruption in a 3D in vitro model
2.3.1 Hypothesis: F-actin disruption improves 3D muscle force
The 2D model is unstable when treated with 3gM CytoD in that the monolayer collapses after
an hour. This weaker cell-substrate adhesion could result in increased active displacements. So
in order to quantify change in forces with skeletal muscle contraction, we developed a stable
3D muscle tissue model.
2.3.2 Experimental model
2.3.2.1 Fabrication of the force sensing support and mount
A 1/16 in optically clear acrylic sheet (McMaster) was cut with rectangular through holes
using an Epilog 120W CO 2 based laser cutter. Also two cantilevers were cut out of 0.125mm
thick kapton sheets (McMaster) using a UV laser cutter with a tiny 0.65mm hole at their tips
for the muscle tissue to pass through. One of the cantilevers was compliant with an estimated
stiffness of 0.34 N/m, while the other cantilever was much stiffer with an estimated stiffness of
-8N/m. Estimations were based on COMSOL 3D elastic FEM simulations of clamped
cantilevers. The concept is to cast a thin cylindrical shaped muscle tissue anchored in 3D
between the two cantilevers and optogenetic stimulation would only lead to minute
displacements of the compliant cantilever which could be recorded using an optical
microscope. The two cantilevers were assembled on the acrylic backbone with further acrylic
cutouts and a silicone gasket as shown in Fig. 14, such that the faces of the cantilevers were
parallel to each other, with a 3mm gap between the two and such that the holes at the tip of the
cantilever were aligned coinciding with each other.
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UV laser cut Kapton cantilevers -
Acrylic base
Sandwich holder with silicone
Fig. 14: Acrylic/kapton base mount for 3D muscle formation and force sensing. The
distance between the faces of the 2 cantilevers is 3mm. Also the entire acrylic base was
inserted to fit snugly in a regular 35mm petri dish.
2.3.2.2 Fabrication of the 3D differentiated muscle bundle
The skeletal muscle tissue was cast using a sacrificial molding technique described in detail
elsewhere'. Briefly, the acrylic mount shown in Fig. 14 was autoclaved at 121C for 45 minutes,
dried for 30 minutes and then placed in a 35mm petri dish using a pair of sterile tweezers. A
sterile stainless steel rod 0.02in in diameter was aligned and inserted through the holes of the
cantilever. 50mg/ml porcine skin based gelatin, dissolved in GM+, which is growth medium
(DMEM + 10% FBS + PS) supplemented with 1 mg/ml E-aminocaproic acid (AA) and warmed
up to 37C was pipetted in to the rectangular cavity containing the steel rod and the cantilevers
as shown in Figures 14 and 15. This was then rapidly cooled in a -20C freezer for 5 minutes to
partially solidify the gelatin liquid. At this point, the gelatin away from the cantilevers was
aspirated using a Pasteur pipette, leaving the gelatin in between the cantilevers intact. This
was cooled down to -20C again for 10 minutes to allow the gelatin to fully solidify. The steel
rod was then removed carefully from the assembly using a pair of sterile tweezers, leaving a
cylindrical cavity in the gelatin for the muscle tissue. C2C12-ChR2 cells were trypsinized and
resuspended in a mixture of 10% Matrigel (Corning, growth factor reduced), 2UI/ml thrombin,
2.5mg/ml Fibrinogen at a cell density of 15M/ml. 10ptL of this solution was inserted into
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gelatin cavity with a 10tL pipette tip held carefully close to the edge of the cylindrical cavity.
Capillary action would typically lead to the gel filling the entire cylindrical cavity. Lastly, 5[tL of
this cell gel solution were pipetted specifically on each end of the cantilever to form cell-based
anchors.
After the gel fully polymerized (20 minutes at room temperature), 2ml of GM+ was added to
the dish and the assembly incubated at 37C overnight. During this time, the cells compact,
generate tension and form an aligned dense tissue of myoblasts. The gelatin melts at 37C and is






Gelatin + steel rod casting
Removal of steel rod to
mold a cylindrical cavity
Cells + ECM injection
Myoblast differentiation
Differentiated C2C12-based 3D
muscle tissue anchored to
cantilevers
Fig. 15: Sequential process for the fabrication of a 3D muscle bundle attached to a
compliant and a rigid cantilever, for measurement of optically stimulated contractile force.
Process adapted from the sacrificial molding process described elsewhere'
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Two days after cell seeding, the medium in the culture was switched to myogenic
differentiation medium DM+ (DMEM + 4% horse serum + PS + AA), supplemented with
5Ong/ml mouse IGF-1. By day 4 after switching, we may start observing some twitches with
optogenetic stimulation. But by day 8-12, the optical stimulation leads to tetanic contractions,
a sign of mature muscle (Fig. 18). The f-actin disruptions are conducted on day 12 (after















Fig. 16: Phase contrast images of the development of the muscle fiber bundle. The




of the differentiation. In this case, the culture was switched to differentiation medium 2 days
























Fig. 17: Image processing pipeline to detect (A) cantilever active movement. (B) A typical
pipeline is shown with the final output of the algorithm being the position of the edge of the
cantilever as shown in red overlaid on top of the raw image. The green lines are many lines
output by the Hough transform algorithm which detects many lines along the cantilever edge.
A linear regression is then performed to estimate a single edge based on all these edged
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(shown in red). The position of this cantilever is tracked over time to estimate the





















Fig. 18: Time-course of active contraction of C2C12 based 3D muscle tissues. The
contractility seems to saturate (or change slower) after day 8 and peak contraction is reached
between day 8-12. The two colored envelopes represent the 68% and 95% confidence
intervals. n = 10 independent muscle fibers were used for this experiment. The contractility of
each muscle fiber was normalized with respect to its respective maximum during the time-
course of differentiation.
2.3.2.3 Optical stimulation and active force quantification
The muscle fibers were simultaneously imaged with phase contrast microscope and optically
stimulated with a 5ms ON, 30Hz blue light pulse using the 1oX objective. Blue light was
supplied through Zeiss filter set #38 (BP 470/40). The optical stimulations of the
differentiated myofibers was conducted through a 1OX objective, yielding an irradiance of
7.5mW mm-2 and controlled via the TTL port of the Lumencor engine through an Arduino Uno
board. Videos of the stimulation were acquired at 30 frames/s or higher by focusing on a small
pixel area (- 150-300 by 300 pixels) at the edge of the compliant cantilever as shown in Fig.
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17. The high frame rate is to ensure that we catch the peak, at which the cantilever stays for
more than 1 frame.
The video was processed frame by frame using software written with Python OpenCV libraries
(Appendix 2). Essentially an edge detection algorithm using the Hough line finding algorithm
implemented on OpenCV was used to find the cantilever edge. The edge was tracked over time
to find the peak displacement.
2.3.3 Results and Discussion
2.3.3.1 3D mouse muscle contractility increases with f-actin disruption
The 3D engineered muscle tissue was treated with CytoD 3VM or DMSO 12 days after
differentiation. Changes in contraction with CytoD application were observed as early as a 2
minutes, but statistically significant differences between the CytoD and DMSO controls are
observed by 15 minutes (p < 0.05) and thereafter as illustrated in Fig. 19.
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Fig. 19: Time-course of active contraction changes of C2C12 based 3D muscle tissues,
within 3 hours. Statistically significant differences (p < 0.05) between the CytoD (n=5) and the
















In line with the results from the 2D myotube experiments, we find that the muscle active force
also increases with f-actin disruption to -2-fold. However, unlike the 2D experiments in which
cell substrate adhesion changed, resulting in increased displacements, the 3D experiment has a
muscle tissue with an intact connection to the kapton cantilever even after CytoD application.
The fact that there is a dramatic increase in the force in this 3D in vitro model add more
evidence to support our hypothesis that f-actin disruption improves skeletal muscle contraction.
We also notice a dose dependent response to CytoD as shown in Fig. 20. The active contractile
force monotonically increases with increasing doses of CytoD. Blebbistatin, a myosin inhibitor
was used as a positive control that is expected to completely inhibit the active force. As
expected SOM of Blebbistatin led to a 0 (non-measurable) optically stimulated active force















Fig. 20 Dose response test of 3D muscle active contractility with Cytochalasin D. The
contractions are measure prior to treatment (Pre-Treatment) as well as 2 hours after CytoD or
DMSO treatment. Normalization is with respect to the contraction prior to treatment. In the
case of Blebbistatin, treatment with 50ptM of this myosin inhibitor completely nullified the
active force within 5 minutes of treatment. ** One-tailed Mann-Whitney test p = 0.00539. NS, p











Furthermore, to prove that the active force improvement is due to f-actin disruption and is not
due to other non-specific side-effects of CytoD, we tested the effect of Latrunculin A. LatA is a
G-actin sequestering molecule which depolymerizes f-actin also, but with a mechanism
different from CytoD, thereby serving as an effective control for non-specific effects of CytoD.
Interestingly, LatA treatment also elicits a muscle phenotype with improved contractility as












Fig. 21 Dose response test of 3D muscle active contractility with Latrunculin A. The
contractions are measure prior to treatment (Pre-Treatment) as well as 2 hours after LatA or
DMSO treatment. Normalization is with respect to the contraction prior to treatment.
The results of the 2 preceding sections (Secs. 2.2 and 2.3), showing an improvement in
skeletal muscle contraction (displacement in 2D or force in 3D) with f-actin disruption,
support the hypothesis that f-actin mechanically impedes contraction.
2.4 Potential drawbacks off-actin disruption
2.4.1 Evolutionary advantages off-actin
It is clear that f-actin disruption seems beneficial to muscle contraction at least in the short
term (2-3 hours of f-actin disruption). However, as skeletal muscle structure is surprisingly








question: "If f-actin disruption is so beneficial to the primary function of muscle, namely
contraction, why did the natural evolution of muscle not optimize for this by itself?" There are
numerous biological regulators of f-actin such as cofilin, gelsolin, formins etc. If having lower
amount of f-actin was evolutionarily beneficial, it is likely that such an optimization would
have happened through natural selection.
There are several possible drawbacks of f-actin disruption, the biggest ones include:
1. Increased cell death
2. Loss of structural integrity of the myotubes
3. Lower fatigue resistance
4. Changes to autophagosomal activity
2.4.2 Increased cell death
2.4.2.1 Hypothesis: f-actin disruption leads to apoptosis and/or cell death
f-actin networks are thought to be essential for the function of most cells. It is plausible that f-
actin disruption induces apoptosis or kills the muscle cells, or at least some fraction of the
cells, given the presumed importance of f-actin.
2.4.2.2 Experiment: Caspase3 qPCR and Live/Dead assay
For RT-PCR, the myotubes were formed on a 2D matrigel coated surface exactly as described
earlier in Section 2.2., except in a 6 well plate instead of the IBIDI-plate. On day 12 after
differentiation, we treated the myotubes with CytoD (0.3[tM) or DMSO for 2 hours and
collected mRNA from the cells using TRIzol (Invitrogen) reagent for RT-PCR analysis. Reverse
transcription was performed using SuperScript VILO cDNA synthesis kit (Invitrogen). Primer
sequences are shown in Appendix 1. Real-time RT-PCR was performed with an Applied
Biosystems 7900HT Fat Real-Time PCR System, using Power SYBR Green Master kit. mRNA of
18s-rRNA was used as the housekeeping gene in all experiments. The RT-PCR experiment was
repeated at least 3 times for cDNA prepared from three batches.
For the live/dead assay, the myotubes were formed on a 2D matrigel coated surface exactly as
described earlier in Section 2.2., except in a 96 well plate instead of the IBIDI-plate. On day 12
after differentiation, we added 50iL of matrigel (Corning, growth factor reduced) on top of the
cells, to keep the cells in place, and negate the effect of any cells detaching from the surface.
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Once matrigel polymerized, 70[pL of DM medium containing CytoD or DMSO was added to the
cells, so that the final concentration of CytoD was 0.3 M. After 52 hours of incubation, the cells
were stained with the ReadyProbes' Cell Viability Imaging Kit (blue/green). The blue Hoechst
dye stained for all nuclei. The green dye only entered cells with compromised plasma
membrane integrity. N = 6 wells were used for each condition. The number of blue and green









Fig. 22 Caspase-3 mRNA quantification (n=3) after 2 hours of CytoD 0.3[tM or DMSO
treatment. p = 0.37. A one-tailed 2-sample t-test was used for statistical significance testing.
2.4.2.3 Result: Mild f-actin disruption does not increase apoptosis or cell death
Running the above assays shows that treatment with 0.3 [M CytoD for 2 hours does not induce
apoptotic gene Caspase-3 significantly differently from controls (Fig. 22). Likewise, the
viability of the cells was not altered significantly by CytoD treatment (52 hours) either as
shown in Fig. 23. Overall these results imply that mild f-actin disruption does not induce






Fig. 23 Cell viability changes (n=6) after 52 hours of CytoD 0.3piM or DMSO treatment. p =
0.46 A one-tailed 2-sample t-test was used for statistical significance testing.
2.4.3 Structural integrity of myotubes
2.4.3.1 Hypothesis: f-actin disruption worsens sarcolemmal integrity
Perhaps cell death or apoptosis does not occur with mild f-actin disruption. However, f-actin
networks are known to be one of the primary cytoskeletal structural scaffold for all cells,
lending structural stability to the cells. So presumably disrupting f-actin has a downside in that
the cell mechanically collapses due to lack of structural integrity. Lack of structural integrity is
observed at the monolayer level when treated with high doses of CytoD (3kM). Monolayers of
C2C12 myotubes detach from 2D surfaces and form a balled up cluster after treatment with
high doses of CytoD (3 M), as described in Section 2.2. However, at lower doses of Cytod
(0.3pM) they do not typically lift off, even though an increased force is observed in response to
these doses. Does the cell lose its structural integrity at these low doses? F-actin is also known
to bolster the mechanical integrity of the plasma membrane. So it is plausible that f-actin
disruption results in a leaky plasma membrane. If the plasma membrane is leaky, it is likely
that cytoskeletal proteins leak out in to the medium. In vivo, this is a situation referred to as
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skeletal muscle injury, which often leads proteins such as Creatine Kinase (CK) to leak at
detectable levels in to the patient's blood. In this section, we also test for Creatine Kinase
activity in the supernatant as a proxy for general cytoplasmic protein leakage because there
are very sensitive assays to detect low doses of CK, and because CK is not a component of the
culture medium.
2.4.3.2 Experiment: Creatine Kinase assay using exercising myotubes
We grew 2D myotubes exactly as described earlier in Section 2.2., except in 96 well plates. On
day 12 after differentiation, we treated the myotubes with CytoD (0.3iiM) or DMSO. Each well
was loaded with 100[tL of medium containing CytoD or DMSO. Just as the treatment began, we
setup an optical stimulation rig underneath the myotubes. 8 LED lights (455 nm, 700 mA,
Mouser Electronics) were aligned below the well plate and this module was placed in a 37C
incubator. The myotubes were stimulated for 2 minutes continuously at 5Hz with a Sms ON
pulse width and repeated every 30 minutes. The voltage drop across each LED was 3.2 V
emitting an average of luminous flux of approximately 15-18 Im. We chose these parameters as
another work from our lab 87 showed that stimulation more often for prolonged period led to
significant fatigue induced damage of the myotubes. After 52 hours of stimulation (just over 2
days), we collected 5jiL of medium from each well and added it to a 96 well plate with the
Creatine Kinase Assay buffer from the Creatine Kinase Assay kit (Biovision). n=6 wells was
used for this test. Spl supernatent from Triton 0.1% treated myotubes was used as a potential
positive control for the presence of Creatine Kinase in the cells. NADH standards were added to
make a standard curve. The reaction was initiated by adding the Creatine Kinase reaction
buffer to the wells and incubated at 37C. The assay is colorimetric and a microplate reader was
used to quantify the absorption of each sample at 450 nm. Measurements were taken every 5
minutes for 30minutes and the rate of change in absorption quantified between the various
samples, compared to the NADH standard curve to estimate the Creatine Kinase activity in the
CytoD 0.3ptM, DMSO and Triton 0.1% treated samples.
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2.4.3.3 Result: Mild f-actin disruption leaves the sarcolemmal integrity intact
As the results indicate, the CK activity in the supernatant medium was not significantly
different from DMSO control (Fig. 24). It was however 4-fold lower than triton 0.1% treated
positive controls. This indicates that sarcolemmal integrity at the stimulation parameters used
was intact compared to triton 0.1% treated positive controls. The baseline level of CK activity
even in the DMSO controls was non-zero because of the presence of some baseline level of








Fig. 24 CytoD treatment likely leaves the plasma membrane intact. It does not significantly
change the activity of Creatine Kinase in the supernatant of the optically stimulated C2C12
myotubes relative to DMSO treated and optically stimulated controls. However, as expected for
positive controls, Triton 0.1% treated samples as expected, show a significant 4-fold increase
in CK activity relative to DMSO controls, indicating the presence of CK in the cells. A one-tailed
2-sample t-test was used for statistical significance testing. NS (p = 0.16) for CytoD (n=6) vs
DMSO(n=6). * p = 7.5*10-7 for Triton (n=3) vs DMSO(n=6)
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2.4.4 Lowered fatigue resistance
2.4.4.1 Hypothesis: f-actin disruption lowers the fatigue index
The F-actin cytoskeleton could in theory act as a restoring force or spring-like element that
helps reduce relaxation times after an active muscle contraction. Disrupting the f-actin could
potentially affect the number of times the muscle can contract and relax freely. So we tested if
the fatigue resistance of skeletal muscle is affected by f-actin disruption
2.4.4.2 Experiment: fatigue loading of 3D muscle for 15 minutes
We fabricated 3D muscle fibers attached to cantilevers and differentiated for 12 days. At this
point, they were treated with DMSO, CytoD 0.3iiM or CytoD 3[tM for 2 hours. 2 hours after
treatment, the muscle fibers were subjected to a fatigue loading stimulus of Sms ON blue light
pulse at 30Hz repeated once every 4 seconds, for 15 minutes total. The optical stimulation
parameters we used are identical to that described in 2.3.2.3. Videos were recorded at 30
frames per second and analyzed as described earlier (see Sec. 2.3). The average force,
normalized to the pre-fatigue force was computed each minute and the change over time of









Fatigue resistance test after 2hrs of treatment
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Fig. 25 Effect of a fatigue loading optical stimulus on muscle active contractility with (or
without) f-actin disruption using CytoD (or DMSO). DMSO controls show a self-strengthening
behavior after 15minutes of fatigue load, while CytoD treated tissues do not. A one-tailed Mann
Whitney U-test was used for statistical significance testing. NS (p>0.05). *(p=0.032). N=3
samples were used for each condition.
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2.4.4.3 Result: Small change in fatigue resistance at short term
We found CytoD treatment does not lead significant fatigue at this short term, but that relative
to DMSO-treated controls, which showed a small but significant strengthening behavior (14%
increase in force after 15 minutes of fatigue), the CytoD treated tissues did not show any such
increase (Fig. 25). This difference is not necessarily deleterious to muscle in terms of not
having a self-strengthening behavior. But it does offer some clues as to the functional role that
f-actin may have during periods of continuous exercise. Future studies should be designed to
look at the response to fatigue loads over longer time periods.
2.4.5 Intracellular organelle or protein damage
2.4.5.1 Hypothesis: f-actin disruption increases autophagy
There are many intracellular organelles and proteins which are associated with f-actin and
perhaps disrupting f-actin may damage these organelles or proteins. If impaired, the cell
typically dissolves these dysfunctional organelles or proteins using autophagy.
Autophagy is an intracellular degradation system that traffics intracellular material, typically
waste or dysfunctional, in to a phagophore, resulting in a double-membrane vesicle called an
autophagosome. The autophagosome then fuses with lysosomes to then degrade the internal
material. In this experiment, we test if mild f-actin disruption with CytoD 0.3ptM (or lower),
which is a concentration sufficient to cause an improvement in force, increases autophagy. If so,
clearly f-actin disruption is harmful to the cell.
2.4.5.2 Experiment: CytoID test of myotubes
We use the CytoID Autophagy detection kit (Enzo lifesciences) to monitor autophagy in the
cells as an indicator of intracellular damage. Briefly, the test uses the CytolD reagent, a
fluorescent dye that selectively labels accumulated autophagic vacuoles. The dye was
optimized to exhibit bright fluorescence upon incorporation into pre-autophagosomes,
autophagosomes, and autolysosomes (autophagolysosomes). This assay helps monitor the
extent of autophagy in the cells.
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Similar to previous sections, we differentiate C2C12 myoblasts to myotubes in a 96 well plate.
We use normal C2C12 cells (non-channel rhodopsin) as the CytoID assay requires blue light
excitation. We did not want optogenetic stimulation to affect the assay. We then treat the cells
with either CytoD (0.3gM and 0.03pjM) or DMSO for 2 hours, and then with the CytoID reagent
for 30 minutes at 37C, and then measure the fluorescence signal. To 0.01% Hoechst was also
added along with the CytoID reagent to count the number of nuclei. N=3 images were taken for
each case, each image containing cells with a total of -10-20 nuclei. The overall green intensity
in each image was computed and normalized with respect to the number of nuclei in that
image to obtain the average green intensity per nucleus. All of these normalized intensities (16
bit values) were then normalized with respect to the DMSO mean intensity. The results were










Fig. 26 F-actin disruption with CytoD does not affect autophagy as indicated by the CytoID
fluorescent based assay. N=3 samples were used for each condition. A 2-sample one-tailed t-














2.4.5.3 Result: No change in autophagy
As shown in Fig. 26, there was no statistically significantly observed increase in autophagy due
to mild f-actin disruption, indicating that there may not be significant protein/organelle
damage at least within the 2 hours of the f-actin disruption tested.
2.5 Conclusion and next steps
The results with our ex vivo muscle assay, 2D myotube based assay and 3D in vitro engineered
muscle tissue based assays indicate that f-actin disruption is very beneficial to creating higher
active forces (-2-fold) with no observable deleterious effects . With mild f-actin disruption
(CytoD 0.3 M) for 2 hours, there was no measurable effect on gene expression of Caspase-3
(apoptotic marker), cell viability, or protein/organelle damage (autophagy). Even with longer
term stimulation (52 hours) in exercising myotubes, there is no significant change in structural
integrity (CK assay). The only possible downside is a slight decrease in fatigue resistance
observed under a fatigue load. Further studies are warranted to understand this tradeoff
(higher force vs lower fatigue resistance) better.
So far, our experiments have been primarily functional in the sense of answering: what doesf-
actin disruption do functionally to the force, to fatigue etc.? In order to understand how f-actin
disruption leads to a functional improvement, we first need to understand which actin
filaments are affected by CytoD. This is the topic of the next chapter.
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Chapter 3: Cytoskeletal changes underlying f-actin disruption
3.1 Introduction
In this chapter, we try to pin-point the cytoskeletal changes that f-actin disruption due to
CytoD treatment causes in order to derive further mechanistic insights. We aim to answer the
following questions:
- Is the functional improvement due to f-actin disruption transient and reversible?
e Which f-actin fibers are disrupted?
- How are the sarcomeric f-actin filaments affects?
- Are there specific sub-categories of f-actin that drive the majority of the functional
improvement we observe?
In order to address some of the questions in this chapter, we use a combination of experiments
such as 1) functional active force assays with dose response and longer term f-actin disruption
as well as reversal of f-actin disruption, 2) live 3D confocal intracellular f-actin visualization, 3)
fluorescence recovery after photobleaching (FRAP) with transfected GFP-actin as well as 4) the
use of more targeted small molecule actin inhibitors.
3.2 Reversibility offorce changes due tof-actin disruption
3.2.1 Hypothesis: CytoD associated force improvement is reversible
The experiments presented in chapter 2 are short term in nature. In all the experiments, we
test the effect of CytoD application on muscle active force improvement in the short term (-2
hours). However, does this force improvement persist beyond 2 hours? Furthermore, what
happens when we wash out CytoD? The binding of CytoD is typically considered to be
reversible, leading to the expectation that after washout of CytoD, the disrupted f-actin may
repolymerize. Does this repolymerization restore the f-actin cytoskeleton to its original
microstructure? How does that affect the functional performance of the muscle tissue? Does
the active force drop again? These are complex questions. In order to start prying apart these
questions, we start by testing the hypothesis that CytoD associated force improvement is
reversible with our functional assay measuring muscle active force generation.
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3.2.2 Experimental methods
As described in section 2.3, we grow and differentiate C2C12-ChR based skeletal muscle
tissues on cantilevers for 12 days and then perform a dose response test to CytoD at 0.3 IM and
3VM, along with DMSO as a control. We measure the active force on day 12, apply the
treatment for a day, while measuring the changes in active force 2 hours and 1 day after the
treatment. Finally, we washout the medium with fresh DM+ medium (without CytoD or
DMSO), wait for a day to recover and then measure the force again. For each muscle fiber that
goes through this sequence of tests, we normalize the force with respect to the corresponding
force prior to treatment. A one-tailed paired t-test was conducted to assess statistical









Fig. 27 The DMSO control tissues show no significant change in active muscle contractility.
Shown are the effects of DMSO application to C2C12 skeletal muscle active contractility 2
hours after treatment, 1 day after treatment, as well as 1 day after washout (which is 2 days
after the treatment was initiated). The active force measured at different times for each device
are normalized to the corresponding pre-treatment force (n=5). Statistical significance tests











3.2.3 Results and conclusions
3.2.3.1 DMSO treatment
As expected DMSO-treated tissues show no statistically significant change (Fig. 27) either with
treatment or washout, with the average force largely being similar throughout the 2 days of









Fig. 28 Mild f-actin disruption with CytoD 0.3pM shows a significant increase in active muscle
contractility within 2 hours (1.6X) and a smaller (but not statistically significant) increase a
day after treatment. The plot shown is the effect of CytoD 0.3pM application to C2C12 skeletal
muscle active contractility 2 hours after treatment, 1 day after treatment, as well as 1 day after
washout (which is 2 days after the treatment was initiated). The active force measured at
different times for each device are normalized to the corresponding pre-treatment force (n=7).
Statistical significance tests were conducted using a paired one-tailed t-test to check if any
potential increases are significant. There is a statistically significant drop in active contraction
1 day after washout of CytoD 0.3 [M indicating at least partial reversibility of CytoD's effect,








3.2.3.2 CytoD 0.3pM treatment
Mild f-actin disruption with lower CytoD dose (0.3pM) appears to lead to a sustainable
improvement in the force. Long term exposure (1 day) to a lower CytoD dose (0.3IM)
increases the active force only slightly (not statistically significant) compared to the peak of
1.6X (reached 2 hours after exposure) (Fig. 28) and in any case does not lead to a decline of
force. To probe the reversibility of this CytoD associated improvement, we washed out the
CytoD 1 day after exposure and measured the muscle active force, 1 day after washout.
Interestingly, the muscle force declines over 20% 1 day after washout (statistically significant).
However, this recovery towards the pre-treatment level is incomplete, as the force is still 50%
higher than the force prior to treatment.
This leads us to 2 hypotheses about the manner in which CytoD affects f-actin:
1) 0.3 pM CytoD does not depolymerize the sarcomeric f-actin even with prolonged exposure (1
day), as 0.3pM CytoD seems beneficial to muscle active force development. We will further test
this hypothesis in Section 3.3 (Spoiler: it does not depolymerize mature sarcomeric f-actin)
2) The CytoD treatment does seem to be partially irreversible, as even after washout of CytoD,
the force remains high.
a) This could either mean that the washout wasn't effective in that some of the CytoD still
remained in the muscle fibers. (We actually rule out this hypothesis later in section
3.2.3.4, by testing the completeness of washout using a fluorescent version of CytoD)
b) Or it could also mean that there has been some permanent cytoskeletal or biological
change due to CytoD application that does not reverse.
3.2.3.3 CytoD 3gM treatment
It seems likely that irreversibility is due to cytoskeletal changes in f-actin disruption that do
not fully recover. If so, increasing the concentration of CytoD to 3pLM for a more severe f-actin
disruption may have a disproportionate effect on the irreversibility.
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Severe f-actin disruption with 3pM CytoD turns out to be deleterious with 1 day of exposure. In
fact there is a statistically significant (Fig. 29) 50% drop in the force relative to the peak force
2 hours after exposure. However, this force is not zero. In fact it is larger than the level of pre-
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Fig. 29 Strong f-actin disruption with Cyto 3pM shows a significant increase in active muscle
contractility within 2 hours (2.6X), a deleterious decrease relative to the peak of nearly 50%
down to 1.4X and a recovery to nearly the level of the 2 hour peak (2.3X) within a day of CytoD
washout. The plot shown is the effect of Cyto 3pM application to C2C12 skeletal muscle active
contractility 2 hours after treatment, 1 day after treatment, as well as 1 day after washout
(which is 2 days after the treatment was initiated). The active force measured at different
times for each device are normalized to the corresponding pre-treatment force (n=10).
Statistical significance tests were conducted using a paired one-tailed t-test to check if any
potential increases are significant. There is a statistically significant drop in active contraction
1 day after washout of Cytod 0.3 pM indicating at least partial reversibility of CytoD's effect,







This further strengthens our hypothesis that CytoD application does not depolymerize the
sarcomeric f-actin, at least not completely. The rationale is that even though there is a force
decline with long term exposure (1 day) relative to the 2 hr peak with 3pM CytoD, the fact that
it is non-zero implies the presence of functional sarcomeres. Interestingly though, 1 day after
washout of 3pM CytoD, the active force recovers to the level of the peak.
This leads to the hypothesis that there are non-sarcomeric f-actin structures within muscle
cells that aid sarcomeric contraction . Furthermore, the force recovery after washout suggests
that such f-actin structures likely recover once CytoD is washed out. Both of these points
support each of our first set of hypotheses (Chap 1) that the presence of some of these non-
sarcomeric f-actin structures may be beneficial to force transmission, while other non-
sarcomeric f-actin structures may mechanically impede contraction. The fact that we find
evidence of both these behaviors under different conditions points to the presence of different
kinds of non-sarcomeric f-actin filaments that may have different roles (we hone in on the
specific nature of these filaments in Sec. 3.6).
Lastly, the reversibility of the force recovery in this case implies that it is unlikely that the
sarcomeric f-actin is depolymerized, as assembly of sarcomeres typically takes several days to
weeks 88,89,90 in C2C12 based muscle systems. Also, it is intriguing that the variability of
responses to 3 M CytoD after 2 hours is much higher than the effect of 0.3[tM CytoD, implying
that the higher dose CytoD likely affects a wider range of f-actin structures.
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Fig. 30 Comparison of the effect of CytoD for longer term (2hrs to 2 days) on muscle
contractility relative to the forces during muscle differentiation. In the case of CytoD 3 [IM and
DMSO, a 2 hour pulse was applied and then washed out to test the recovery and reversibility
long term. This was compared with a continuous mild f-actin disruption with CytoD 0.3IM for
days. Clearly, both the high dose (3RM) pulse of CytoD and the low dose continuoud treatment
both led to sustainable improvement in active contraction beyond the DMSO pulse control and
relative to the maximum force during differentiation (all fibers were normalized with respect
to their respective peaks during days 2-12 of differentiation. The colored envelopes around
each means curve (black, blue, green and red) represent 68% and 95% confidence intervals.
3.2.3.4 Pulsed high-dose CytoD & continuous low-dose CytoD treatment
Given that high dose CytoD affects the muscle deleteriously after long term exposure (1 day),
we tested if a short pulse of CytoD 3pM for 2 hours, followed by a washout could lead to a
persistent improvement. Interestingly it does as shown in Fig. 30. Furthermore, for two days
after the washout, we find that the active force improvement persists.
just as before, this could be due to permanent cytoskeletal rearrangement during those 2
hours or incomplete washout of CytoD.
We rule out the possibility of incomplete CytoD washout by testing CytoD washout
characteristics using a fluorescent version of CytoD, called CytoD EverFluor-TMR (Setareh
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Biotech). We test its penetration in to a C2C12-based 3D muscle fiber and washout using
fluorescence imaging. Normal C2C12 cells without ChR2-tdTomato was used to minimize red
background because this CytoD EverFluor-TMR emits red fluorescence. The experiment was
to treat the muscle fibers with CytoD for 2 hours and then washout the CytoD, all while
imaging the fluorescence intensity at 6 locations along the muscle fiber and the background,
before and after treatment/washout.
As seen from Figs. 31 and 32, there is a significant drop in CytoD-EverFluor intensity after
washout (almost imperceptible in the first row of images in Fig. 31). As shown in the
quantification of Fig.32, the peak intensity of CytoD 2 hours after treatment is -1000-fold
higher than the pre-treatment background intensity. 1 day after washout, this gap between the
muscle fiber intensity and the no CytoD background drops to -5-fold, i.e., there is a -200-fold
drop in fluorescent CytoD intensity relative to the 2 hour peak. Likewise, there is a 700-fold
drop after 2 days of washout.
Given this, it is unlikely that CytoD washout was incomplete. So the likely hypothesis that may
explain the persistence in force even 2 days after washout is some sort of cytoskeletal
rearrangement. Finally, we also plot the force evolution when the muscle fiber was
continuously treated with low dose CytoD (0.3 M) and we find that the force improvement lies
in between the DMSO controls and the high-dose pulsed CytoD treatment. However,
importantly, even 2 days in to this stimulation, the muscle force improvement seems to persist,
reemphasizing our earlier point that with mild f-actin disruption, long term treatment may not
be disruptive.
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respect to 2 day
washout image
Fig. 31 Fluorescence intensity of CytoD EverFluor-TMR measured 2 hours after treatment and
after washout. (A) a phase contrast image showing a typical 3D muscle fiber. (B) The first row
of images contains the raw images used for quantification purposes in Fig. 32. The second row
contains histogram normalized versions of images in the first row. The normalization with
respect to the 2 day washout image in order to make the visibility of the muscle fiber clear,
while still maintaining the relative intensity. Clearly there is a significant drop in intensity,
almost imperceptible by 1 or 2 days after washout. Scale bar 300im
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Fig. 32 Fluorescence intensity of CytoD EverFluor-TMR measured 2 hours after treatment and
after washout. All the intensities were normalized between 0 and 1 with respect to the
maximum average intensity measured as well as the minimum (throughout the experiment).
The background intensity could vary from day to day, due to changes in environmental
conditions as well as variations in the laser. So the intensity values corresponding to zero
CytoD concentration are - 6*104 for both the pre-treatment and 2 hour cases. In the 2 hour
image, the background is high because it contain CytoD-EverFluor. However, the intensity of
the muscle fiber is even higher than that as it seems that CytoD reacts with f-actin and
accumulates inside the muscle. 2 hours after treatment, the average intensity on the muscle
fiber is -1000-fold larger than the pre-treatment background. One day 1 after washout, the
muscle intensity drops to being 5-fold larger than background (-200-fold reduction) and on
day 2, it drops to being 1.4-fold larger than background (i.e. a -700-fold reduction compared










3.2.3.5 Conclusion and next steps
Overall, it seems that f-actin disruption with CytoD follows a complex pattern. The functional
assays in the previous sections 3.2.3.2-3.2.3.3 lead us to the following hypotheses:
1) Sarcomeric f-actin is not affected by low dose CytoD (or CytoD penetration in to tissues
in incomplete)
From the previous section, we found that even long term (2days) exposure to
high CytoD does not affect the active contractile force negatively. This could
either mean that sarcomeric f-actin is not disrupted by CytoD application or
that CytoD does not completely penetrate the tissue. We test both these
hypotheses in sec 3.3 and 3.4.
2) Low dose CytoD disrupts some of the dynamic f-actin which may recover quickly after
washout. We test this hypothesis in sec 3.5.
3) There are some stable f-actin filaments that help sarcomeric contraction. We test this
hypothesis in sec 3.6.
3.3 Dynamics of CytoD penetration
A
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Fig. 33: Diffusion of Cytochalasin D - Everfluor conjugate through a muscle fiber. (A)
Confocal fluorescence timelapse images of the Cytochalasin D - Everfluor conjugate
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penetrating the 3D muscle tissue. Scale bar in images is 100 [m. (B) Quantification of the
fluorescence intensity variation, with time. All intensities are normalized with respect to the
same maximum 16-bit greyscale spectrum. Every line at any given time point represents the
average intensity across the muscle fiber averaged over 30 cross sections along the length of
the muscle.. 3 of the cross sections are shown in the first image in (A).
3.3.1 Hypothesis: CytoD fully penetrates the muscle 3D tissue within a day
The fact that long term exposure to CytoD still doesn't eliminate active contractility leads us to
believe either that CytoD does not penetrate the tissue fully, or (if it does) it does not
depolymerize the sarcomeric f-actin. In this section we test the former of these 2 hypotheses.
3.3.2 Experimental methods
As described in section 2.3, we engineer a C2C12-based 3D muscle fiber using normal C2C12
(non ChR2-tdTomato), differentiate it for 12 days. The engineered muscle fibers after 12 days
of differentiation are -80 im in diameter. We then test the dynamics of penetration of Cyto-
EverFluor TMR, a red fluorescent version of CytoD at 0.3p.M concentration using 3D confocal
timelapse microscopy with a confocal laser scanning microscope (FV-1000, Olympus, Japan).
3.3.3 Results and conclusions
As illustrated in Fig. 33, we focus on a confocal slice in the middle of the muscle fiber. As
shown in Fig. 33, we find that within 20 minutes, the CytoD penetration saturates at the outer
edges and has begun to plateau within the center of the muscle fiber. Part of the reason the
intensity in the center is lower is also due to laser excitation and emission attenuation through
a thick muscle tissue. It is clear from Fig. 33 that within 24 hours (the duration of the long
term exposure), CytoD-EverFluor will penetrate the entire muscle (in fact the timescale seems
to be 10s of minutes for am -80im diameter muscle fiber). CytoD-EverFluor (M.W. 887
g/mol) has a slightly higher molecular weight of CytoD (M.W. 507 g/mol), which makes it
likely that CytoD diffuses through the tissue faster (ignoring charge effects).
Overall, this experiments rules out the possibility that CytoD does not reach all the muscle cells
during the long term exposure (1 day). In fact, from Fig.33., it seems that even 2 hours after
treatment, the entire muscle must be saturated with CytoD.
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3.4 Visualization off-actin breakdown
3.4.1 Hypothesis: Sarcomericf-actin is not broken down by CytoD
From the results of Sec 3.3, it is clear that all muscle cells must be exposed to CytoD by the 2
hour timeframe. For the CytoD to not eliminate the active contraction, we hypothesize that it
must not depolymerize the sarcomeric f-actin within this time frame. To reframe this, we also
wanted to understand what changes occur in the f-actin cytoskeletal structure within 2 hours
of exposure to CytoD. This is because, our experiments in Chapter 2 showed significant
increases in active force starting at 30minutes and plateauing close to 2 hours. So we designed
an experiment to answer the following questions:
1) Are the sarcomeric f-actin filaments depolymerized by CytoD 0.3 pM in 2 hours?
2) Are the non-sarcomeric f-actin filaments depolymerized by CytoD 0.3 IM in 2 hours?
3.4.2 Experimental methods
We use Sir-Actin (Cytoskeleton Inc.), a fluorescent far-red small molecule dye that binds to f-
actin filaments and helps visualize structural changes in f-actin. According to established
protocols with Sir-Actin (Cytoskeleton Inc., Spirochrome), we use the dye at very low
concentrations (100nM) so as to not affect the f-actin dynamics because of the dye.
We differentiate C2C12-ChR cells on matrigel coated IBIDI-plates in 2D (as described in section
2.2), differentiate the cells in DM+ for 12 days. At this point, we check for tetanic contractions
using the blue light from a fluorescence lamp (see section 2.2). If the cells are contractile and
tetanic (a sign of mature C2C12s), we expose the cells to DM+ containing 100nM of Sir-Actin
dye, incubating at 37C overnight.
At this point, we use aspirate the medium from the top of the cells, add 150[IL of matrigel
(Corning), allow matrigel polymerization for 20 minutes at 37C in the incubator, and then add
2ml medium on top, also containing Sir-Actin. The purpose of the matrigel is to provide some
ECM for the cells to stick to in order to prevent complete cellular collapse during the imaging
with CytoD. We then found a variety of cells in the 2D IBIDI-surface. Some cells contained
mature sarcomeres, with primarily sarcomeric f-actin, while others contain immature
sarcomeric f-actin filaments. Others still had partially differentiated myotubes (without a clear
sarcomeric f-actin pattern). This provides a great test bed to observe the effect of CytoD on
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various kinds of f-actin filaments (sarcomeric, non-specific f-actin mesh, non-sarcomeric f-
actin stress fibers etc). In real muscle fibers, there is a combination of these different kinds of f-
actin filaments.
3.4.3 Results and discussion
The results indicate that sarcomeric f-actin filaments are not depolymerized by CytoD, while
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Fig. 34: Visualization of f-actin in mature and immature myotubes using Sir-Actin and confocal
timelapse microscopy reveals that sarcomeric f-actin in mature myotubes is not
depolymerized by CytoD 0.3[tM. However, a small fraction of the non-sarcomeric f-actin is
depolymerized with CytoD. For instance, in window 2: the arrows mark areas with f-actin
clustering at T=30 and 150mins(dark rounded spots), which is typical when filamentous actin
breakdown appears (also see Fig. 36B for more obvious clustering). Also shown using arrows
in window2 (between T=60 and 90mins) as well as in window 3 (T= 90mins) is the sudden













In order to parse this out, we performed confocal timelapse imaging simultaneously with a
more mature myotube with sarcomeric f-actin filaments, as well as an immature myotube
without sarcomeric f-actin. Myotubes with sarcomeric f-actin also have non-sarcomeric f-actin
but as Sir-Actin stains all f-actin (as seen in Fig. 34), it is often difficult to pinpoint the non-
sarcomeric f-actin in mature sarcomeric myotubes. This is the reason we also chose to image
more immature myotubes which are typically found in 2D differentiated myotubes along with
more mature myotubes. The prime assumption in this experiment being that the dynamics of
the non-sarcomeric f-actin in the immature myotubes are similar to the non-sarcomeric f-
factin found in mature myotubes.
In one of these imaging sessions, illustrated in Fig. 34, both a mature and immature myotube
are found on the same frame, which makes a comparison easier. These myotubes were
exposed to 3[tM CytoD for 2.5 hours. As seen in Fig. 34, the sarcomeric f-actin structure
remains even after 120 minutes of exposure to CytoD. However, within the same timeframe,
there are several non-sarcomeric f-actin filaments shown to be depolymerized. We see several
hallmarks of f-actin depolymerization in the non-sarcomeric f-actin filaments, such as f-actin
clustering (annotated by pink arrows in Fig. 34), disappearance of uniform background f-actin
which are likely sub-diffusion limit sized thin filaments that don't appear as distinct filaments





















Fig. 35: Visualization of f-actin (Sir-Actin) in mature sarcomeric myotubes with CytoD 0.3IM
application using confocal timelapse microscopy reveals that while sarcomeric f-actin in
mature myotubes are not depolymerized by CytoD 0.3 [M, the non-sarcomeric non-specific f-
actin (darker) around the periodic f-actin structures do get depolymerized. This is also
illustrated in the intensity line plot showing that the periodic structures remain after 12 hours,
while the overall intensity level comes down, due to depolymerization of some of the non-











Fig. 36: Visualization of f-actin (Sir-Actin) in immature sarcomeric myotubes as well as
immature non-sarcomeric myotubes with CytoD 0.3pM application using confocal timelapse
microscopy reveals that (A) Even the periodic sarcomeric f-actin gets disrupted if the myotube
organization is immature as seen in A with the imperfectly aligned developing sarcomeric
structure. (B) Several of the stress-fiber like f-actin filaments in the non-sarcomeric immature
myotubes are severed. As the pink arrows indicate, what starts off as an area with many stress-
fiber like f-actin structures become f-actin clusters by ~1hr indicating snapping and balling up
of the stress fiber-like f-actin. By -2hrs, the CytoD treatment depletes that cytoskeletal area of
most of the stress fiber-like structures, leaving an almost plain white image. Scalebar is 10pm.
We performed further investigation observing f-actin in myotubes that are at different stages
of differentiation for longer durations of CytoD 0.3pM exposure (up to 12 hours). Fig. 35 shows
that when the sarcomeric myotubes are mature, the sarcomeric f-actin is not depolymerized by
CytoD. However in these mature myotubes, the non-specific background f-actin (dark non-
periodic areas around the sarcomeric structures) structures are depolymerized (Fig. 35).
Interestingly, such disappearance of the non-specific background actin, with an intact
sarcomeric pattern has been observed earlier9' in cardiomyocytes treated with Latrunculin B,
yet another actin depolymerizing agent. These dark structures however slowly depolymerize





likely much more stable than f-actin in pre-sarcomeric immature myotubes (Fig. 36B). There
are cytoskeletal changes that occur in the non-sarcomeric f-acin in these myotubes within 2
hours. However these changes are much more subtle (can be seen in videos and in Fig. 34 if
















Fig. 37: (A) Quantification of the non-sarcomeric stress-fiber like f-actin breakdown in pre-
sarcomeric immature myotubes shows that the distribution of linear f-actin filaments gets
skewed towards shorter filaments with CytoD treatment (B) There seem to be many more
stress-fiber like f-actin filaments with CytoD treatment. i.e. CytoD treatment converts a few
long f-actin filaments into many more shorter filaments. (C) Quantification is performed by
manually counting stress-fiber like f-actin structures and measuring their length using the
length tool of ImageJ software. An example of an stress-fiber like actin filament in shown with














(subjectively) based on the location where there appears to be a branching of the bundled
stress-fiber like f-actin or a clear stop.
In immature myotubes, the immature sarcomeric f-actin structures do get disrupted by CytoD
as shown in Fig. 36A. This also follows from. earlier efforts 92 which show that immature
sarcomeric f-actin filaments, also called pre-myofibrils are not capped (unprotected ends),
while mature sarcomeric f-actin filaments, myofibrils have capped (protected) ends, with the
protein CapZ capping the barbed end of f-actin and tropomodulin capping the pointed end. So
it follows that mature sarcomeric f-actin is indeed protected from CytoD, which induces
depolymerization typically by binding to the barbed end of f-actin. Lastly, f-actin filaments in
pre-sarcomeric immature myotubes are disrupted quickly in 1-2 hours by CytoD (Fig.36B).
Furthermore, a quantification of this non-sarcomeric f-actin reveals that the number of f-actin
filaments increases while the size of each filament reduces upon CytoD treatment. This trend
clearly reflects the f-actin depolymerization trend qualitatively illustrated earlier in Fig. 34 and
36.
3.4.4 Conclusions and next steps
It is clear that CytoD doesn't disrupt the sarcomeric f-actin in mature myotubes, while it does
disrupt the non-sarcomeric stress fiber like f-actin filaments often severing a few long f-actin
filaments into many short ones. Severing the stress fiber like f-actin filaments seems counter-
intuitive to the mechanism of actin of CytoD which induces thin filament depolymerization by
binding to the barbed end. We hypothesize that this is an indirect effect due to adhesions
holding the stress fiber like f-actin intact being disrupted. From observations of timelapse
videos of this severing phenomenon, it almost seems like a rope that is in tension suddenly
snapping leading to thinner ropes which also release some tension. There are many categories
of f-actin as discussed later in Sec. 3.6. So far, it is still unclear which f-actin filaments are being
disrupted by CytoD.
In order to perform a more detailed characterization of this, we perform 2 kinds of studies:
1) A study of the dynamics of f-actin polymerization and turnover using fluorescence
recovery after photobleaching (FRAP). This is the topic of Section 3.5
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2) The use of more specific f-actin inhibitors to understand which f-actin filaments
impede muscle contraction and which ones help. We discuss these experiments in
Section 3.6
3.5 The shifting polymerization dynamics off-actin
3.5.1 Hypothesis: CytoD depolymerizes the fast-turnover f-actin filaments
There are several ways to classify f-actin structures within a cell: long stable stress fiber like f-
actin vs short rapidly turning over mesh-like f-actin, f-actin capped by capping proteins such as
tropomodulin and CapZ vs others that are not, sarcomeric f-actin vs non-sarcomeric f-actin etc.
In order to classify all these different kinds of filaments broadly in to 2 quantifiable categories,
we use the fluorescence recovery after photobleaching (FRAP) experiment with GFP-tagged
monomeric actin.
By bleaching a window of these monomers, and observing the recovery times, we can compute
the actin turnover timescales. In this case, we categorize all the fluorescent actin present into 3
regimes: free monomeric actin, dynamic (fast turnover) f-actin and immobile stable f-actin.
The choice of "3 regimes" is on purpose' in this case, as we would like to subcategorize the
filamentous actin in to those that turnover in the 10s-1min timescale, and those that turnover
much slower (eg. > 10min timescale). The former we define here as dynamic f-actin and the
later as stable f-actin.
As illustrated in Fig. 38, the FRAP experiments involving fluorescently tagged actin monomers
are complex to interpret due to the different processes that contribute to the fluorescence
recovery. The early phase of the recovery is rapid and dominated by the diffusion of the GFP-
1 When analyzing GFP-actin FRAP experiments, one needs to use a minimum of 2 separate phases to
account for the various timescales of fluorescence recovery: rapid recovery due to monomer diffusion and
slower recovery due to filamentous actin. However, the filamentous actin phase could potentially be
subdivided in to many categories (n>7). There are many sub categories of f-actin (sec 3.6) which all have their
characteristic timescales. Depending on the experimental question, for instance in investigating differences
between two specific sub-divisions within the dynamic filaments, we may have to fit multiple exponentials to
the same ~1min timescale data as well. For example see 93 Fritzsche, M. et a/. Cytoskelletal actin dynamics
shape a ramifying actin network underpinning immunological synapse formation. Science Advances 3 (2017)..
But that is a 2rd order level of detail that would be good, but something we are not investigating in this
study. We are just looking at the average turnover rate of all filaments that recover in the ~10sec to 1min
timescale, and thus sub-categorize the filamentous actin into dynamic filaments (~10s to 1min timescale) and
stable filaments (whose recovery time is in the 10s of minutes i.e. much longer than the duration of this
experiment which is 3 minutes long).
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tagged monomeric actin due to its size relative to the GFP tagged f-actin diffusing in from other
areas 94. This is typically complete within a few seconds depending on the area of the bleach
window. In the next phase, the recovery is dominated by incorporation of GFP monomers
within the bleached dynamic f-actin filaments. This process has a timescale typically much
slower than monomer diffusion and is in the 10s of seconds. Finally, there are bleached f-actin
filaments that are so stable (slow turnover) due to capping proteins and/or stabilized by
nebulins, tropomyosins, adducing, caldesmon and calponins that in the timescale of the
experiment (2-3 minutes), they do not recover. This could involve a combination of sarcomeric
and non-sarcomeric f-actin and we lump them together as the immobile fraction or stable f-
actin in this experiment.
Pre-bleach Bleached area Unbleached GFP-actin
-- -- ---- -- monomers diffuse in
070
% 44 W
Dynamic f-actin F-actin turnover Rapid initial
turnover complete. . . monomer diffusion
FRAP saturates ("1 i am ic complete (1sfilaments tm sae
min timescale)
Fig. 38: Schematic of fluorescence recovery after photobleaching of GFP-tagged actin
monomers. Monomer recovery occurs first and is the most rapid (GFP-tagged monomers
indicated by the green particles and the background green used to doubly emphasize the
location of unbleached GFP-tagged monomers). F-actin turnover driven recovery is slower
than the diffusion of monomers (10X slower), and so can be considered to occur after
monomer recovery is complete. This is schematically indicated by the grey (bleached) f-actin
filaments acquiring some green particles (unbleached monomers) from the
barbed/polymerizing end of f-actin. Some of the bleached f-actin filaments recover much more
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slowly (10s of minutes) due to protective capping proteins. These are schematically shown to
never recover (always grey after bleaching) in the timescale of the experiments conducted (2-3
minutes).
The timescales of the recovery of the 3 actin sub-compartments have an order of magnitude
difference from each other (monomeric actin -1s, dynamic f-actin 10s-1min, stable f-actin >
10mins). The contribution to the recovery curve of stable f-actin is limited as we only analyze
the first 3 minutes of recovery. So an implicit assumption in the FRAP analysis is that the
plateau of the exponential recovery curve fit to the dynamic f-actin recovery region marks the
amount of stable f-actin (see Fig. 39). Furthermore as monomeric diffusion is an order of
magnitude faster than dynamic f-actin turnover (see Fig. 39 and 40), we utilize this to
temporally decouple the 2 processes and thereby simplify the interpretation of the FRAP
recovery profile. We discuss further details in the next section.
3.5.2 Experimental methods
We grow and differentiate C2C12 myoblasts on an IBIDI-treated surface to form myotubes on
2D (see section 2.2). We use unmodified C2C12 cells for this as we want the cell not to be
bluelight sensitive (as the C2C12-ChR2 cells are) because we want to have GFP-actin in these
cells. One day before the FRAP assay (day 11 after differentiation), we added 100 L of
Bacmam 2.0 Cell Light Actin-GFP reagent (ThermoFisher) in 1ml of DM+ to the cells for GFP-
Actin transfection. Overnight -incubation of this reagent leads to expression of a GFP-tagged
actin construct delivered through a BL safe insect virus, Baculovirus.
After verifying the GFP-actin expression in the cells using a confocal line scanning microscope
(FV-1000, Olympus, Japan) with a 60X oil immersion objective (NA 1.30), 150 L of matrigel
was polymerized on top of the IBIDI plates so that cell adhesion to this ECM prevents dramatic
cell movements when treated with CytoD. A bleach window was defined using the stimulus
settings of the FV-1000 software such that the height of the window was slightly larger than
the width of the myotube (Fig. 39). This is so that all diffusion of GFP-actin in to this window
occurs from the left or right, making it effectively a 1D diffusion problem. Furthermore, the
width of the window was chosen to be 2[im so that diffusion into this effective length scale is
complete within is (timescale ~ L2/D, with a D - 3*10-8cm^2/s for monomeric actin, timescale
~ (1km)A2/(3*10- 8cmA2/s) < 1s). Lastly the pinhole of the confocal was completely opened
(800 im) so that the entire depth of the cell was bleached. We also ensured that there are no
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out-of-plane cells that contribute to the recovery curves. This is possible as most cells are in a
plane on 2D.
There are several imaging parameters listed below that need to be optimized depending on the
desired FRAP study. The optimal parameters completely photobleach all the GFP across the
cell in the bleach window, minimize photobleaching while capturing the recovery and capture
the recovery at an appropriate frame rate and duration so as to capture the phenomenon of
interest. More details about these choices follow.
1. Photobleaching
a. Laser intensity, laser duration time for photobleaching
2. Recovery
a. Laser intensity
b. Pixel resolution of capture
c. Size of the photobleaching window
d. Frame rate of recovery capture
e. Duration of capture
The photobleaching parameters (laser intensity, duration) described below were chosen to as
to completely bleach all the GFP to the level of the background so that any recovery of
fluorescence in the window of recovery occurs due to diffusion of GFP-tagged monomers from
outside of the window (as shown in Fig. 38 and 39) and consequent incorporation in to the f-
actin. Bleaching of the window was performed with the DAPI, FITC and TRITC lasers all set at
80% of the maximum power, with bleach settings being 200pts/pixel, ipx = 0.1km in the XY
plane, and with 5 frames of sequential bleaching. The pre-bleach image was acquired, followed
by 5 bleaches within the bleach window and then the post-bleach recovery profile (of average
intensity within the bleach window) was obtained. Each pixel was exposed for 2 s in line
scanning mode and the effective framerate of acquisition this depends on the overall number























Fig. 39: A typical FRAP recovery curve and pictures from an actual experiment. C2C12
myotubes with GFP-actin monomers are bleached with a rectangular window covering the
entire width of the cell throughout the entire depth. Scalebar is 10[m. By plotting the intensity
recovery within the bleach window over time and by using the remaining image to compute
the rate of photobleaching we obtain a corrected recovery curve, which has a rapid diffusion
limited recovery in the -1s timescale followed by a slower turnover limited recovery.
The parameters for capturing the fluorescence recovery are chosen as follows:
As shown in Fig. 39 with the FRAP recovery data from one cell sample, photobleaching
does occur. We lowered the laser power to -2%, used a pixel resolution of ipx = OlIm in the
XY plane and an exposure time to 2pts/px in order to minimize photobleaching, while ipx =
0.1im in the XY plane optimizing for maximal signal. Using too low a laser intensity (<2%) is
not optimal as it would decrease signal:noise too much even though photobleaching would be
even smaller. With the above parameters we kept photobleaching during recovery to < 20%.
We correct for the effect of photobleaching on the fluorescence recovery curve by computing
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the change in average intensity of the non-bleached areas. By quantifying photobleaching
during acquisition in areas outside the bleach window (Fig. 39), we use this information to
normalize the raw recovery curve.
The choice of frame rate and duration of capture are also optimized based the
following criteria. The upper bound to the frame rate is limited by the pixel exposure time,
pixel resolution and number of pixels because we use a line scanning confocal microscope. The
upper bound is also dependent on the duration of recovery capture and photobleaching. Using
a high frame rate limits the duration of capture, which significantly affects which phenomena
we capture. For eg. to capture diffusion, we may only need a few seconds of capture (see above,
diffusion within a bleach window having a length scale of lum has a is timescale). However, to
capture f-actin turnover which has a timescale between -10s-1min, we may need to capture
several minutes of data. The lower bound of the frame rate depends on the Nyquist criterion.
To capture the different recovery regimes, we use different frame rates based on the Nyquist
criterion (frequency of information capture must be > 2*frequency of phenomenon observed).
For instance, rapid diffusion may require a much higher frame rate than slower f-actin
turnover. In order to capture the initial rapid diffusion limited fluorescence recovery, this
optimization resulted in an effective frame rate of -33Hz and duration of -5s. For the f-actin
turnover, we acquired images of larger areas leading to an effective frame rate of -5Hz (which
is sufficient to capture recovery curves with timescale of 10s of seconds) and duration of
-180s. Alternatively, we could have captured the entire recovery curve with the highest
possible frame rate to capture all phenomena. But this would have minimized the pixel area
(and thereby increase noise in the measurement). Due to our use of a line scanning confocal
microscope, imaging a larger area leads to lower frame rates. Moreover, using the highest
frame rate, also dramatically increases the rate of photo-bleaching and this limits the duration
of capture. Hence the high frame rate used for short timescale diffusion limited recovery (<is),
cannot be used to capture the dynamic f-actin recovery (which has a 3 minute duration).
Overall, it must be clear from the discussion above that choosing parameters for FRAP is a
complex multi-dimensional optimization problem involving several competing tradeoffs. The
final choice of our parameters is empirical and these choices may not necessarily represent the
global optimum. However, the key to performing a valid comparison between the control
(DMSO treated) and the condition (CytoD treated) is to ensure that the FRAP parameters used
for both cases are identical, thereby preventing any internal bias. The exact choice of
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parameters (frame rate 5Hz vs 2Hz, duration of 120s vs 180s) introduces a global selection
bias in terms of analyzing the recovery of specific f-actin filaments with a certain range of
timescales captured by the specific parameters. But as long as the parameters are fixed
between the control and condition cases, there is no internal comparison bias.
In this experiment, we sub-categorize the total GFP-actin in to GFP-actin present as monomers,
incorporated in dynamic f-actin (turnover timescale -1 minute) and stable f-actin (bleached
stable filaments don't recover in the timescale of minutes). By using a total capture time of 3
minutes, we ignore the recovery of stable f-actin filaments (including sarcomeric f-actin) that
recover in the timescale of 10s of minutes. Moreover, the monomeric actin recovery is
complete within the first few seconds (see description below).
So , in order to compute the timescale of dynamic f-actin turnover, the fluorescence recovery
profile from 10s to 180s was fit with an exponential curve such as (a-b*eA(-t/tc)) similar to
works described elsewhere 9s. In this equation, 'a' is the total recovered fraction at t -> 00,
which is the sum of the monomer associated recovery and dynamic actin associated recovery.
a-b represents the monomer fraction (this approximation works because the monomer
recovery timescale of -1s << 180s, so effectively (a-b*eA(-t/tc)) evaluated at t=0 is a-b which
gives the fraction of monomer recovery). Hence, (a-(a-b)) = b is the fraction of dynamic f-actin.
tc is the timescale of dynamic f-actin turnover. Lastly, (1-a) is the immobile fraction, which
represents the stable f-actin, stable in the sense that it recovers at a timescale tstable >> -1min
timescale of this experiment. The choice of 10s is an engineering approximation. If the
timescale of diffusion is 1s, then 10s represents 10 timescales in an exponential recovery,
which is 99.995% of completeness of diffusion recovery. So to find the dynamic actin turnover
time, fitting an exponential to the curve after 10s ensures that the diffusion timescale does not
affect the estimated turnover time. We use 5-9 cells typically for each condition (DMSO, CytoD
0.3ptM, CytoD 3[tM) and compute the FRAP recovery curves before and 1 hour after treatment
for each of these cells. These experiments are paired because we observed the same cell before
and after treatment. Based on the curve fitting exercise described above we compute the
relative ratios of G-actin, dynamic F-actin and stable F-actin as well as the turnover timescale
of dynamic F-actin, both before and after the treatments.
In Fig. 41 we have plotted these numbers as a ratio of (actin fraction after treatment)/(actin












Fig. 40: The first few seconds of the FRAP recovery curve, plotted based on 19 individual FRAP
experiments conducted at different regions along 3 different myotubes. The rapid initial rise is
driven purely by diffusion of monomers. We use this recovery profile to compute the
timescale of diffusion.
3.5.3 Results and discussion
We used a framerate of 33Hz to acquire the first 5 seconds of images, which gave us the rapid
diffusion recovery (Fig. 40). By fitting this curve to an exponential curve (1-e^(-t/Tdiff)), we
obtained the diffusion timeconstant (Tdiff ~ L2/D). This let us estimate the order of magnitude
of the diffusion constant D ~ 1.OS*10 -8 +/- 2.4*10-9 cm2 /s. This value is similar in magnitude
to monomeric actin diffusion constants of ~3*10-8 cm2/s reported in literature 94, which















Fig. 41: Relative change ratio of the fractions of the various actin compartments(actin
monomer, dynamic f-actin and stable f-actin). The Y-axis represents the ratio of (Dynamic F-
actin fraction after treatment)/(Dynamic F-actin fraction before treatment) etc for the various
compartments - Dynamic (corresponding to 'b' in the fit equation (a-b*e^(-t/tc)) ), stable F-
actin (corresponding to '1-a') as well as Monomeric actin ('a-b'). The various treatment
conditions (DMSO, CytoD) are shown in shades of green. The red dots represent the mean
values. * p = 0.029 with a one-tailed unpaired 2-sample t-test with respect to the DMSO
controls. N=5 was used for DMSO and CytoD 3piM conditions. N = 9 was used for the CytoD
0.3[tM condition.
Treatment with CytoD did not lead to statistically significant changes among the various actin
fractions. Largely this makes sense because even the f-actin visualizations with Sir-Actin did
not show a very significant breakdown of f-actin everywhere. The changes were more subtle.
The only exception to this being the dynamic f-actin change ratio which is statistically
significantly higher with CytoD 3 M than DMSO controls. In general there is a trend towards
decreasing stable actin and increasing dynamic f-actin with higher concentrations of CytoD
(Fig. 41). Also, CytoD breaks down many long f-actin filaments (Fig. 37) which explains the
trend of reducing stable actin with many of these filaments becoming dynamic at higher CytoD
doses.
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As there is not a significant change in most of the actin fractions, we wanted to identify if the
distribution of filaments within the dynamic f-actin pool may have changed. CytoD is most
likely to affect filaments that turnover fast.
In order to answer this question, we compute the average turnover time of the dynamic f-actin
which represents the population average of the turnover times of all the dynamic f-actin
filaments in the cell. We represent this as a ratio normalizing the timescales of f-actin turnover
of each cell with respect to the corresponding timescale prior to treatment of that cell. As
shown in Fig. 42, there is a significant increase in the timescale of dynamic f-actin turnover
with CytoD concentration. For this to be possible, CytoD must be converting the dynamic f-
actin filaments with relatively fast turnover time to ones with a slower turnover rate. This
seems plausible given the mechanism of action of CytoD that is known to bind to the barbed
end, preventing polymerization. So it follows that this binding slightly reduces the turnover
speed (increases turnover time). Furthermore, as the relative fraction of dynamic f-actin
doesn't vary significantly at low CytoD doses (Fig. 41), this suggests that there are not too
many CytoD sensitive filaments. This is also reflected from our FRAP experiments illustrated
Fig. 41 showing that the monomer fraction does not change significantly. If there was a
significant amount of CytoD sensitive filaments among the dynamic f-actin filaments, the
monomer fraction must have increased significantly (which did not). At the same time, several
non-sarcomeric stress fiber like f-actin filaments get severed and exhibit a shortening
characteristic of a severed "rope" in tension as illustrated in Figs. 34, 36 and 37.
To summarize, CytoD treatment leads to depolymerization of a small fraction of dynamicf-actin
filaments which leads to shortening and severing of several stress-fiber like non-sarcomeric f-
actin filaments. This effect of severing of stress-fiber like f-actin is not characteristic of the
known mechanism of CytoD. It must be an indirect effect of CytoD. The working hypothesis is
that the CytoD sensitive filaments stabilize the long stress-fiber like non-sarcomeric filaments.
Most interestingly, this effect is sufficient in some manner to improve the contraction
significantly. This could perhaps be due to the reduced mechanical hindrance of these f-actin





Fig. 42: Relative change ratio of the timescales of dynamic f-actin turnover with the various
treatments. Significance tests were 1-tailed t-tests. The turnover time change with CytoD
0.3[iM is barely statistically significant, while the change due to CytoD 3ptM is highly
statistically significant relative to the DMSO treated controls. A one-tailed unpaired 2-sample t-
test with respect to the DMSO controls was used to test for statistical significance. N=5 was
used for DMSO and CytoD 3pM conditions. N = 9 was used for the CytoD 0.3plM condition.
3.6 Targeting f-actin subcompartments
Our tests so far are limited to CytoD (majority of tests) and Latrunculin A(Chapter 2), which
both disrupt f-actin and show a functional improvement in muscle contraction. CytoD is
somewhat specific in the kind of f-actin it targets (dynamic f-actin with an uncapped or
weakly-capped barbed end), leading to slightly "less dynamic" (slower turnover) dynamic f-
actin filaments, which are slightly shorter and more in number.
However, Latrunculin A is not nearly as specific. As Latrunculin A acts by actin monomer
sequestration, it is quite likely to affect all f-actin filaments that exchange monomers with the
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monomeric pool, which is the vast majority of all f-actin subtypes. Not only is it likely to affect
the dynamic f-actin pool that is involved in active exchange of monomers with the monomeric
pool, but it also likely affects spontaneous actin nucleation, branched f-actin formation, formin-
mediated actin assembly etc. by sequestering monomers. Clearly it is not specific.
In all the experiments so far, we have disrupted only the CytoD sensitive dynamic (uncapped)
f-actin filaments. In this section, we would like to answer the following questions, which
require targeting other f-actin sub-compartments with specific small molecule inhibitors:
- Is the improvement of muscle contraction an effect that is limited to disruption of just
the CytoD sensitive dynamic f-actin filaments?
e Would disrupting other f-actin subdomains also lead to a functional improvement?
Identifying more specific f-actin sub-compartments whose disruption may be functionally
beneficial could be a starting point towards developing more targeted actin disrupting
therapeutics as well as understanding the mechanism underlying the functional improvement.
3.6.1 Introduction to the different non-sarcomericf-actin subtypes
There are a large variety of non-sarcomeric f-actin structures within cells, typically formed and
defined by their association to a range of actin binding proteins (italicized below). The 3
primary structures of non-sarcomeric f-actin that initially form are:
1) Short linear f-actin filaments typically formed by spontaneous nucleation and
elongation of ATP bound G-actin monomers.
2) Long linear f-actin filaments nucleated throughformins that are typically used in the
contractile ring during cell division or in stress fibers. The formins protect the barbed
end of f-actin from capping proteins which leads to increased lengths of the filaments
formed through formins. Profillin also aids in improving the speed of this.
3) Branched f-actin formed by branching nucleators such as Arp2/3 and its regulators
such as WASP and the SCAR/WAVE complex.
There are many ways in which these 3 types of f-actin are modified and rearranged, which
could lead to several different secondary structures or localization of these structures to
different parts of the cell. These include 96:
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a) Cortical f-actin bound typically to membrane and membrane proteins through actin-
binding proteins such as a-actinin, annexin II, a-catenin, BPAG, dystrophin, ERM
proteins, plectin, spectrin, Sla2 (HIPMR), talin, tensin, utrophin and vinculin
b) Stable f-actin stabilized, scaffolded or chaperoned by proteins such as adducin,
caldesmon, calponin, nebulin and tropomyosin
c) Capped f-actin through barbed end capping proteins such as CapZ formins and tensin,
as well as pointed end capping proteins such as ARP2/3 and tropomodulin
d) Tensile f-actin involved in creating cytoskeletal tension through myosin.
e) Actin linked to other cytoskeletal filaments. Eg. Actin linked to intermediate filaments
(IF) through spectrin, to microtubules (MT) through tau as well as to IF and MT
through plectin, BPAG, MACF and MAP2.
f) Cross-linked f-actin through cross-linking proteins such as a-actinin, spectrin and
transgelin
g) Bundled f-actin through crosslinking proteins
a. in microvilli such asfimbrin, scruin, cillin and espin
b. in filopodia such asfascin and a-actinin (and)
c. in stress fibers such as a-actinin andfascin
The ideal experiment would be to fabricate a 3D muscle fiber on our cantilever setup (Chapter
2), measure its contractility and then perform an acute disruption of any one of the specific
proteins above to measure the change in contractility. If beneficial (or otherwise), such an
experiment would elucidate the role of these various f-actin filaments in force transmission.
While the tools of modern molecular biology such as Si-RNA, CRISPR based gene regulation
could be used to develop knock down models (at the RNA level), or CRISPR based gene editing
to make knock out models, these tools are still not ideal for acute in situ disruption
experiments due to differences in delivery, slower time of action etc. So we limit this study to
small molecules that may be targeted towards specific actin subdomains to understand their
influence on muscle active contractility.
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The following are the small molecule inhibitors that specifically disrupt 4 categories of f-actin:
1) Uncapped dynamic f-actin: Cytochalasin D is known to bind to the barbed end of f-
actin typically depolymerizing the dynamic filaments which shorten from their pointed
end.
2) Long linear f-actin filaments: SMIFH2 is a specific small molecule inhibitor of
formins. It is known to interact with FH2: formin homology domain 2, which typically
prevents formation of long linear f-actin (by blocking formin mediated actin assembly),
and/or disrupts long f-actin associated with formins.
3) Branched f-actin: CK666 is a specific small molecule disruptor of the ARP2/3
complex, which effectively prevents the formation of branched f-actin
4) Stable tropomyosin stabilized non-sarcomeric f-actin: TR100 and ATM3507 are
small molecule inhibitors of the non-sarcomeric tropomyosin isoform Tpm3.1, which
could be used to disrupt f-actin filaments associated with Tpm3.1.
As we have investigated the effect of CytoD in detail, this section is focused on inhibitors for
the other three actin subdomains. We differentiate C2C12-ChR2 cells in 3D as before on our
cantilever device and measure the active formation before and after treatment with different
doses of the various inhibitors.
3.6.2 Inhibiting formin-mediated actin assembly
As shown in Fig. 43, treatment with SMIFH2 leads to a statistically significant improvement in
active contraction at the high concentrations. Inhibiting formins typically leads to halting of
formin mediated f-actin assembly of long f-actin filaments. This must mean the average f-actin
length in the cell must be smaller with SMIFH2 treatment. This is very interesting because
even CytoD treatment leads to shorter f-actin filaments albeit, with a different mechanism. The

















Fig. 43: Treatment with 100pM SMIFH297, a small molecule inhibitor of formin homology
domain 2 improves active skeletal muscle contractility within 2 hours of treatment. This is
likely due to inhibition of the FH2 domain of formins which leads to disruption of formin
associated f-actin filaments and/or inhibition of formation of such filaments as formin is an f-
actin nucleator. At SMIFH2 doses of 20pM or lower, no improvement in contraction was
observed. Statistical significance testing was performed with a one-tailed unpaired 2-sample t-

















3.6.3 Disruption ofArp2/3 mediated branched f-actin
As shown in Fig. 44, treatment with CK666 (at 100M), an Arp2/3 complex inhibitor leads to a
gradual drop in the active contraction to nearly 50% 1 day after treatment. No functional
improvement was observed. This leads us to conclude that the branched Arp2/3 mediated f-
actin actually helps sarcomeric force transmission in muscle. This is the first data point in
support of the hypothesis that f-actin (specifically the Arp2/3 mediated filaments) may have
an important role in force transmission (Sec. 1.3, hypothesis 1). Future works are warranted to







Fig. 44: Treatment with CK666 100 [M, an inhibitor of the Arp2/3 complex leads to a gradual
decline of contractility. The data for the change in contraction 2 hours (not-significant) and 1
day (statistically significant) after treatment with CK666 100 IM are shown. This makes it
plausible that the branched Arp2/3 mediated f-actin filaments do help in sarcomeric force
transmission. At SMIFH2 doses of 20gM or lower, no statistically significant change in















Statistical significance testing was performed with a one-tailed unpaired 2-sample t-test with
respect to the DMSO controls.
3.6.4 Tropomyosin stabilized stable f-actin
We treated another set of 3D differentiated muscles on cantilevers with the anti-tropomyosin
compounds TR100 and ATM3507 98,99 (gifts from Dr. Peter Gunning) in order to investigate the
role of tropomyosin stabilized f-actin in force transmission. Both these compounds are
targeted towards the non-sarcomeric tropomyosin isoform Tpm3.1. As shown in Fig. 45 and
46, treatment leads to a dose dependent decline in the muscle active force. There is a -60%
decline in active force with 2 hours of exposure to TR100 5ORM. Lower doses had no effect. In
the case of ATM3507 50[tM, there is a 90% decline within 2 hours, with lower doses showing
slightly lower, yet significant declines.
TR100 and ATM3507 are compounds with such different structures that both bind to Tpm3.1,
that the functional decline observed is clearly an effect of targeting the tropomyosins. Clearly f-
actin filaments stabilized by the tropomyosin Tpm3.1 have an important role to play in
sarcomeric force transmission. Interestingly, a similar result was also reported with mice
which when treated with TR100 presented a muscle dystrophic phenotype 100. This is the
second data point in support of the hypothesis that f-actin (in this case the Tpm3.1 stabilized







Fig. 45: Treatment with TR100, an anti-tropomyosin compound targeting the non-sarcomeric







Statistical significance testing was performed with a one-tailed unpaired 2-sample t-test with









Fig. 46: Treatment with ATM3507, another anti-tropomyosin compound targeting the non-
sarcomeric tropomyosin isoform Tpm3.1 leads to a decline in muscle contractility 2 hours
after treatment. Statistical significance testing was performed with a one-tailed unpaired 2-
sample t-test with respect to the DMSO controls.
3.6.5 Conclusions
We find that disrupting the dynamic f-actin (CytoD) or long linear f-actin by preventing formin
mediated assembly could be beneficial to muscle contraction. In both these cases actin
disruption leads to lower filament length. However, disruption of either Arp2/3 mediated
branched f-actin or tropomyosin Tpm3.1 stabilized f-actin seems deleterious to muscle active
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Chapter 4: Mechanical softening improves muscle force
4.1 Mechanical hypothesis
Our evidence so far supports both the hypotheses discussed in Sec 1.3. We have evidence in
support of the hypothesis that certain f-actin filaments (the CytoD sensitive dynamic f-actin
and the formin-mediated filaments) mechanically impede skeletal muscle contraction (Sec. 2.2,
2.3, 3.2, 3.3, 3.4, 3.5, 3.6.2). However in Sec 3.6, we also found evidence in support of the other
hypothesis that Arp2/3 mediated f-actin and Tpm3.1 stabilized f-actin may be required for
skeletal muscle contraction. In this chapter, we don't explore these filaments (Arp2/3
mediated f-actin and Tpm3.1 stabilized f-actin) any further. We focus on unraveling the
mechanical hypothesis underlying CytoD mediated f-actin disruption.
As f-actin is typically a protein providing structure and mechanical support to cells, perhaps
the following mechanical analogy could provide a potential hypothesis: the muscle sarcomeric
contraction system is a bio-mechanical motor facing both an internal (its own stiffness) and
external resistance (the stiffness of the cantilever/anchor). By disrupting the f-actin
cytoskeleton and shortening the non-sarcomeric f-actin filaments, we are likely creating a
more loosely connected cytoskeleton, one whose mechanical stiffness could potentially be
lower. If so, the muscle now needs to contract against less of a resistive stiffness. This could
provide a possible causal relationship for the observed improvement.
Hypothesis: f-actin disruption with CytoD improves skeletal muscle contraction due to a
lower internal mechanical resistance. For this hypothesis to be true beyond all the evidence
collected so far (Sec. 2.2, 2.3, 3.2, 3.3, 3.4, 3.5, 3.6.2) , the following criteria must all be true:
1) No increase in muscle sarcomeric force producing proteins
2) The internal mechanical resistance has to be lower due to CytoD treatment
3) The timescale of mechanical resistance changes must match the timescale of force
improvements
4) No change in energy consumed (increased force output could be explained potentially by
increased energetic input)
5) No change in metabolic capacity of the mitochondria which processes the glucose to ATP, a
molecule used in the majority of energetic process in muscle cells including sarcomeric
force production.
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6) Lastly, reversal of the phenomenon, namely stabilizing f-actin must lead to decreased
active contraction
We test each of these hypotheses in the following sections.
4.2 Changes in sarcomeric force producing proteins
Based on the results in Chapter 2, we know that CytoD treatment leads to a force improvement
within 30 minutes. This rapid response likely rules out excessive production of sarcomeric
force associated proteins as the cause of the improved force. This is because sarcomeric
protein assembly (myofibril formation) typically takes several hours (eg. in Xenopus myocytes
101) to several days (eg. in C2C12 based systems 88,89). Sometimes, in C2C12 based systems it
could even take weeks under certain culture conditions 90. It follows that in C2C12 based
systems improved sarcomeric assembly should take much longer than the 30mins to 2hrs
timescale in which the force improvement was observed. In order to confirm this, we use RT-
PCR to look for changes at the gene expression level of the following sarcomeric proteins:
myosin heavy chains MHC2B and MHC1, as well as myosin light chains MYL3 and MYL19 (Fig.
47). None of these genes change in expression significantly after 2 hours of CytoD 0.3[tM
treatment. Furthermore, the expression of 14 other genes (Fig. 47) that have important roles
in protein synthesis, energetic metabolism, protein degradation, apoptosis and Ca2 + regulation
were also not altered significantly after 2 hours of exposure to CytoD (Fig. 47). RT-PCR
methods used are identical to methods described earlier (Chapter 2, Sec. 2.4.2). A full list of
gene names and PCR primer sequences are in Appendix 1.
These results show that in the time window that we observe a force increase (30mins to 2hrs),
we do not see significant changes in expression of almost several important genes involved in
muscle force production and energetic metabolism etc. Further studies must be conducted in
the future to understand gene expression changes that may occur due to long term f-actin




























Fig. 47: Gene expression analysis using RT-PCR for 21 genes including housekeeping gene 18s
rRNA, with CytoD 0.3 M application for 2 hours. The relative expression levels are colored
with a log2 scale (10-3 to 103). No significant changes in gene expression were found. There
were 3 samples used for both CytoD and the control (DMSO), labeled 1-3. A 2 sample t-test was
used to obtain significance levels of the relative expression, with samples made in triplicate.
4.3 Changes in cell level stiffness with AFM
4.3.1 Hypothesis: CytoD lowers the apparent elastic modulus of myotubes
If CytoD treatment were to lower the internal mechanical resistance faced by a contraction cell,
it follows that this change would be reflected through a change in the mechanical stiffness of





C2C12-ChR2 cells were differentiated on 10cm tissue culture treated polystyrene dishes for 12
days with the same protocol as described earlier. Once the myotubes were differentiated, we
performed AFM indentation using a pyramid shaped cantilever on 30 cell locations on
myotubes with application of DMSO or 3iiM CytoD for 30 minutes in the 37C incubator.
AFM Force-distance measurements were acquired with a JPK Nanowizard-I (JPK
instruments, Berlin, Germany) interfaced to an inverted optical fluorescence microscope
(Zeiss). Pyramid shaped AFM cantilevers (MLCT, Bruker, Karlsruhe, Germany) were used.
Cantilever spring constants were determined using the thermal noise method implemented in
the AFM software (JPK SPM, JPK instruments). Prior to any cellular indentation tests, the
sensitivity of the cantilever was set by measuring the slope of force-distance curves acquired
on stiff regions of the petri dish. For measurements on cells, we used cantilevers with nominal
spring constants of 0.01 N.m-1). The cantilever tip was brought into contact with the cells using
an approach speed of 5 um/s until reaching a target force of 10nN. This was followed by
retraction of the cantilever. The approach force-indentation curve was fit (up to 1pm
indentation depths to neglect effects of the substrate) with a Hertzian model to estimate the
apparent elastic modulus. A Poisson's ratio of 0.5 was assumed for the purpose of this
estimation.
4.3.3 Results and discussion
As shown in Fig. 48, the AFM indentation experiment clearly shows that the apparent elastic
modulus of C2C12 myotubes decreases with AFM indentation. This conclusively proves that at
the single myotube level, the mechanical stiffness drops with CytoD treatment.
The f-actin visualizations in Chapter 3 showed us that CytoD treatment led to severing,
shortening and clustering (balling-up) of the stress fiber like f-actin filaments (Sec. 3.4).
Furthermore, subtle changes to the background intensity stain of f-actin depolymerization
were observed indicative of f-actin depolymerization (Fig. 34 and 35 in Sec. 3.4). However,
FRAP analysis showed that the depolymerization was not so significant as to lead to a
significant increase in relative fraction of monomeric actin (Fig. 41). In light of these subtle
cytoskeletal changes, one may question if any of these changes would have led to a lowering of
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internal mechanical resistance. The AFM indentation experiment conclusively shows that this
is the case. The mechanical consequence of all these changes to the cytoskeletal f-actin
structures is in fact -50% lower stiffness.
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Fig. 48: AFM indentation of C2C12-based myotubes reveals a drop in mechanical stiffness. (A)
AFM approach retraction curve (red) with a curve-fit (green) to the approach curve. A Hertz
model was fit to the data to compute the apparent elastic modulus. (B) CytoD treatment clearly
lowers the apparent elastic modulus relative to DMSO treated controls (AFM) by 50%. N=30
cell indentations were used for this test.
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4.4 Changes in tissue level stiffness with a micro-tensile test
4.4.1 Hypothesis
In the last section, we proved that CytoD treatment does significantly lower the cell level
stiffness of the myotubes in a 2D environment. However, in a 3D in vivo like environment, such
as in the 3D engineered muscle construct, the cells likely have slightly different mechanical
properties and might respond differently to cytoskeletal drugs such as CytoD. In this section,
we test the hypothesis that the axial stiffness of the muscles also drops with CytoD treatment.
4.4.2 Experimental methods
To test this hypothesis, we constructed a micro-tensile test setup, adapting an apparatus
similar to that described in Sec. 2.1 as shown in Fig. 49.
Micromanipulator used to
stretch-relax the muscle tissue
A
Cantilever edge in focus
B s- Muscle tissue out of focus C
Image processing pipeline
Area with a 3D muscle tissue
attached to a compliant and rigid
cantilever I
CAD models of the
tissue mount fixture
with the slidable holder
(top and bottom views)
Fig. 49: Micro-tensile testing of a muscle tissue. (A) The setup used for testing of the axial
stiffness of a muscle tissue. The typical muscle tissue used in this study is -100im in diameter,
3mm in length anchored between two clamped kapton cantilevers (orange in color), one
relatively compliant and the other relatively rigid (as described earlier in Chapter 2). The setup
allows simultaneous measurement of the active contraction by observing the movement of the
compliant cantilever (see the text in Sec. 4.2.2). Furthermore, the slidable rigid cantilever
allows the muscle to be stretched and relaxed by 50 ptm steps, which also allows estimation of
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the axial stiffness. For a sense of scale, the circular tissue mount fixture is -6cm in diameter.
The distance between the cantilevers in the fixture is 3mm. (B) The image processing pipeline
used for stiffness computation. The first image represents the raw image of the initial position
of the compliant cantilever edge. The second image represents difference image between the
initial and final positions of the compliant cantilever as the rigid cantilever is moved to stretch
the muscle tissue. The thickness of the bright rectangular zone is the displacement. An edge
detection algorithm similar to the one described in Chapter 2 (see appendix 2) is used to detect
the two edges of the bright strip. (C) Shows the cantilever position displacement (black), the
cantilever displacement (red) and the normalized stiffness (blue).
C2C12-ChR2 cells were used to form and differentiate a 3D muscle fiber in situ on two kapton
cantilevers (as in Sec. 2.3). One of the kapton cantilevers is compliant and has a stiffness of
0.34 N/m while the other is more rigid and has a stiffness of 8N/m. To this point, the setup and
protocol is identical to the in vitro experiments described in Chapter 2. The main difference is
that the rigid cantilever is attached to a slidable base (as indicated), which allows us to apply
defined stretch relaxation steps each with a 10m accuracy as it is connected to a
micromanipulator. Thus this setup allows simultaneous measurements of stiffness and
contractility changes.
The active contractility changes are computed exactly as described before, by observing the
changes in deflection of the compliant cantilever. The axial stiffness changes are computed
using a tensile testing methodology. Briefly, the micromanipulator was used to stretch the
muscle tissue by moving the stiffer cantilever away from the muscle tissue by ALrigid = 50pm.
The corresponding change in position of the compliant cantilever was recorded ALcompliant. This
allows us to estimate the axial stiffness k = ATensionaxial / ALmusce = Kcantilever*ALcomphiant /(ALrigid
- ALcomphiant) - ALcompliant /(ALrigid - ALcompliant). In this equation, Kcantiiever is the stiffness of the
compliant cantilever, which cancels in the comparison as it does not change with CytoD
treatment. This was followed by a relaxation by 50ptm and the corresponding change in
position of the compliant cantilever recorded too. Such stretch relaxation steps were repeated
several times (as illustrated by the red dots in Fig. 49) to obtain a consistent measure of the
axial stiffness. We chose to perform 30 total stretch-relax steps based on preliminary testing
that showed very little variation in the stiffness measured after a few initial steps (see an
example of this data in Fig. 49C, which shows 80 stretch relax steps).
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Given this metric, we treat the fully differentiated muscle tissue at day 12 with CytoD 3jIM and
then simultaneously observe the change in contraction and change in axial stiffness every 10
minutes for 1 hour.
4.4.3 Results
As seen in Fig. 50, the axial stiffness of the muscle (n=5) drops by about 50%. At the same time
the active contraction rises by about 45%. Moreover the two changes (drop in stiffness and
rise in contraction) occur on very similar timescales ~ 1 hour. This provides further support
for the mechanical hypothesis that the drop in internal stiffness is the cause of the improved
contraction.
1.6
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Fig. 50: CytoD treatment leads to a simultaneous decrease in axial tissue stiffness and
improvement in active contraction as measured by the micro-tensile testing assay. The
























4.5 Changes in energetic consumption
4.5.1 Hypothesis: CytoD treatment does not increase glucose consumption
In this chapter, we have been using the analogy of a mechanical motor as a model of the muscle
tissue contraction. We been measuring changes in the active contraction, a measure of the
output of the "muscle motor" as well as the change in stiffness, a measure of the energetic
barrier imposed by the muscle internally to contract itself. In order for the increased active
forces to be explained purely by decreasing internal resistance, the energetic consumption of
the tissue shouldn't increase either. Going with the "muscle motor" analogy, drawing higher
currents from the power source could also lead increased output of the motor. In order to rule
out this possibility, we test the hypothesis that CytoD treatment does not increase energetic
consumption. As a proxy of energetic consumption, we use changes in glucose concentrations
in the culture medium as a measure of the energetic consumption.
4.5.2 Experimental methods
As before, we differentiate C2C12-ChR2 cells on matrigel coated 96 well plates for 12 days. We
changed the culture medium 12 hours prior to CytoD treatment with 100pLL of fresh DM+
containing 4.5mM glucose so that the cells are not metabolically starved. At this point, we
aspirate the medium, add 50iL of matrigel on top of the cells so that the cells stay in place even
if f-actin disruption dislodges it. Once the matrigel polymerizes (20minutes at 37C), we add
70pL of medium on top containing CytoD or DMSO (n=6) so that the final concentration of
CytoD is 0.3[tM. 52 hours after treatment, the supernatant medium was collected and the
change in glucose concentration was estimated using the colorimetric test from the Glucose
detection kit (GO assay, Sigma Aldrich). This was then normalized to the number of nuclei in
each well to (correct for cell number variations from well to well in order to estimate the
glucose consumption rate per cell per hour.
4.5.3 Results
As shown in Fig. 51, the baseline glucose consumption rate (GCR) did not change significantly
due to CytoD treatment. This adds further evidence to the hypothesis that the energetic








Fig. 51: CytoD (0.3[tM) treatment does not significantly change the baseline glucose
consumption rate of the differentiated C2C12 cells. A 1-tailed 2 sample t-test was used for
statistical significance testing.
4.6 Changes in energetic signaling and metabolic activity
4.6.1 Hypotheses
From the last section, we found that there is no change in glucose consumption due to f-actin
disruption. But perhaps the manner in which glucose is metabolized within cells or the
pathways it activates might lead to a different cellular energetic state. In order to further probe
changes to the energetic metabolism of these muscle cells due to f-actin disruption, we would
like to test 3 hypotheses in this section:
Hypothesis 1: F-actin disruption does not affect AKT phosphorylation.
Phosphorylation events happen within minutes and could potentially be within the timescale
of the observed force changes in the cell (30mins to 2hrs.). Moreover, AKT phosphorylation is a
master regulatory signal for a host of downstream biochemical pathways related to energetic
activity.
Hypothesis 2: F-actin disruption does not change overall cellular metabolism. For
overall cellular metabolic activity, wanted to test for changes in the TCA (Kreb's) cycle.
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Hypothesis 3: F-actin disruption does not change mitochondrial activity.
Mitochondrial activity is important because it is the center of ATP production in the cell and
ATP hydrolysis drives repeated muscle contraction.
If any one of these hypotheses are proven wrong, we can't rule out the possibility that changes
in cellular energetic or metabolic activity contribute to the improved active force observed
upon f-actin disruption.
4.6.2 Experimental methods
For hypothesis 1: Western blot ofAKT phosphorylation.
C2C12-ChR2 cells were cultured in 6 well plates, differentiated as described earlier. After 12
days of differentiation, they were treated with DMSO, CytoD 0.3IM and CytoD 3IM for 2 hours.
Cells were lysed with a cell lysis buffer containing RIPA buffer, a protease inhibitor cocktail
(Cell Signalling) and PMSF. Proteins were quantified using the BCA assay and 20 [Ig of protein
per condition was subjected to SDS/PAGE using 4-12% (wt/vol) gradient gels (Life technology,
NuPAGE Novex, Bis-Tris), transferred to nitrocellulose membranes, and the relative
concentrations assayed by immunoblotting. Experiments were conducted in triplicates.
Primary antibodies were used for mouse anti-tubulin (Thermofisher, b-Tubulin loading
control, 1:1000), mouse anti-actin (Thermofisher, b-actin loading control, 1:1000), AKT
(1:1000 Cell Signaling), pAKT s473(1:500, Cell Signaling), pAKT t308(1:500, Cell Signaling). As
for secondary antibodies, an anti-mouse IgG, HRP-linked Antibody (Cell Signaling) and an anti-
rabbit IgG, HRP-linked Antibody (Cell Signaling) were used. HRP substrate was used for
chemiluminescent analysis.
For hypothesis 2: MTT assay for mitochondrial succinate dehydrogenase activity.
For the MTT assay, the MTT Cell Growth Assay Kit (SigmaAldrich) was used. We cultured and
differentiated C2C12 cells in 96 well plates for 12 days. n=4 wells was used for each condition.
After 12days, they were treated with varying doses of CytoD or DMSO for 1 hour at 37C. After 1
hour, the MTT reagent was added to the different wells, followed by further incubation at 37C
for 4 hours. The formazon formed was spun down using a plate centrifuge, the medium was
aspirated and 100L DMSO added to each well and mixed vigorously to fully dissolve the
purple crystals. A plate reader was used for quantification.
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For hypothesis 3: TMRE assay for changes in mitochondrial membrane potential.
The TMRE molecule is a cell permeant, positively-charged, red-orange dye that accumulates in
active mitochondria due to the relative negative charge of the mitochondria. Depolarized or
inactive mitochondria have decreased membrane potential, due to which they fail to sequester
TMRE. Similar to the MTT assay, we differentiate C2C12 cells in 96 well plates, treat them with
CytoD (0.3piM) and then use the TMRE reagent. At higher CytoD doses, the monolayer collapses
and it becomes impossible to compare the relative fluorescence with respect to DMSO treated
controls. N = 5 was used for this experiment. After 20 minutes of incubation with the TMRE
reagent at 37C, we use a fluorescent readout to quantify the relative changes.
4.6.3 Results and conclusion
As seen in Fig. 52, AKT phosphorylation does not change with CytoD treatment. Likewise
cellular metabolic activity (Kreb's cycle) tested through the mitochondrial succinate
dehydrogenase activity doesn't change either (Fig. 53). Given that the mitochondrial
enzymatic activity doesn't change with f-actin disruption, one might expect the average activity
of mitochondria to not change either. This is reflected by the TMRE assay conducted (Fig. 54).
None of these 3 assays point towards energetic activity change. While these 3 results don't
conclusively prove that the energetic state of the cell doesn't change, they do represent some
of the earliest indicators of change in energetic activity of a cell. This evidence together with
the gene expression data (Sec 4.2) also showing no significant change, does add significant



















Fig. 52: CytoD treatment (0.3 [M or 3ptM) for 2 hours does not significantly change the
phosphorylation of AKT at the 2 phosphorylation sites (Ser473 and Thr308). A) Western blots
showing pAKT expression levels for both sites Ser473 and Thr308 along with AKT as a
function of CytoD concentration. P-tubulin and P-actin are also shown as loading controls B)
Averaged results showing the ratio of phosphorylated AKT to total AKT. A 2-sample 1-tailed t-




















Fig. 53: CytoD treatment (0.3pM or 3[tM) does not significantly change cellular metabolic
activity as assessed by an MTT assay. See text for details about the time of exposure. A 2-









Fig. 54: CytoD treatment (0.3 M) does not significantly change mitochondrial activity as







accumulates only in active mitochondria. A 2-sample 1-tailed t-test was used for statistical
significance testing NS (p > 0.05). N=3 was used for these experiments.
4.7 F-actin stabilization reverses the phenomenon
4.7.1 Hypothesis: Stabilizing f-actin decreases the active force
All our experimental data lack any evidence pointing towards a non-mechanical origin of the
force improvement. If the mechanical hypothesis illustrated in Fig. 55 is true, then the reverse
of this phenomenon, must also be true: Stabilizing f-actin decreases the active-force.




In order to test this hypothesis, we repeat our 3D C2C12 based muscle contractility assay of
Chapter 2, with f-actin stabilizing chemicals jasplakinolide (Santa Cruz Biotech.) and phalloidin
(Santa Cruz Biotech). Both are small molecules that bind competitively to the same site of f-
actin. Phalloidin is known to bind to f-actin and stabilize it. Prior works 102 have shown that
phalloidin treatment of reconstituted actin networks increase the network stiffness by a factor
of 2. Jasplakinolide too is known to stabilize f-actin and also enhance f-actin polymerization by
inducing nucleation. Furthermore, there is prior evidence 103 that jasplakinolide increases the
mechanical stiffness of living cells (mouse embryonic fibroblasts). If our mechanical
hypothesis is true, treatment with these chemicals must decrease the active force. We use a
5ptM concentration of jasplakinolide as this concentration was shown earlier1 04 to affect actin
dynamics in quail myotubes. A high phalloidin concentration of 100 M is used because
phalloidin is highly impermeable to cells. Prior works have shown that incubation of
cardiomyocytes with this 100 M phalloidin affects the actin cytoskeletal dynamics' 05 . DMSO is
used as a control in both cases.
4.7.3 Results
As illustrated in Fig. 56 and 57, treatment with jasplakinolide and phalloidin do indeed
decrease the active muscle force. Not unexpectedly jasplakinolide acts much more rapidly
than phalloidin (perhaps due to its higher permeability into cells than Phalloidin). Prior works
104 investigating the actin cytoskeleton in myotubes show a rapid response to jasplakinolide as
early as 30minutes. However, to the best of our knowledge, with phalloidin treatment in live
cells, a response earlier than 5 hours of treatment has not been reported 0 5 .
In any case, this is a demonstration that f-actin polymerization (or stabilization) decreases the
active force. Together with all the previous results in this chapter, this result adds significant

















Fig. 56: jasplakinolide 5 tM treatment decreases active contractility of C2C12 based 3D
engineered muscle by 25% within 2 hours of exposure and 33% within 24 hours of exposure.

































Fig. 57: Phalloidin 100pM treatment decreases active contractility of C2C12 based 3D
engineered muscle by 25% within 24 hours of exposure. 2 hours after treatment, there was no
significant change in contractility relative to DMSO treated controls. Statistical significance
testing is based on the 1-tailed 2 sample t-test
4.8 Conclusion
In conclusion, all 6 criteria we listed in Sec. 4.1 that need to be satisfied for the mechanical
hypothesis to be true have been met, adding significant evidence to support the mechanical





Hypothesis Experiment t ese
True/False
No increase in muscle sarcomeric force
RT-PCR TRUE
producing proteins
The internal mechanical resistance has to be AFM, micro-tensile
TRUE
lower due to CytoD treatment test
The timescale of mechanical resistance
changes must match the timescale of force micro-tensile test TRUE
improvements
No change in energy consumed (increased Glucose
force output could be explained potentially by consumption test TRUE
increased energetic input)
No change in metabolic capacity of the AKT
Not proven
mitochondria which processes the glucose to phosphorylation, FALSE
ATP, something used MTT, TMRE
Lastly, reversal of the phenomenon, namely Jasplakinolide,
stabilizing f-actin must lead to decreased Phalloidin effect on TRUE
active contraction contractility
Chapter 5: Summary, Applications and Future Studies
5.1 Summary
We started this thesis with two basic questions: 1) What is the role of the non-sarcomeric f-
actin in skeletal muscle sarcomeric force transmission? 2) What would happen to the
sarcomeric contractile force if the non-sarcomeric f-actin were disrupted? The 2 prevailing
schools of thought in the field (prior to this thesis) pointed in opposite directions:
(a) Disrupting non-sarcomeric f-actin is deleterious to muscle force transmission perhaps due
to its role in linking the sarcomeres to the costameres or due to the f-actin serving as a scaffold
to the sarcomeres of sorts. Or (b) Disrupting non-sarcomeric f-actin enhances muscle force
transmission due to the reduction of internal mechanical resistance posed by the cytoskeleton
to its own contraction. As in most complex systems, the thesis has revealed the answer to be: it
depends on which f-actin sub-category.
Depleting certain classes of non-sarcomeric f-actin filaments, namely the dynamic f-
actin structures that are CytoD sensitive, as well as the formin-associated f-actin filaments,
enhance skeletal muscle contraction. These actin filaments seem "detrimental" to muscle
function. This comes also with the added benefit of no significant changes to any of the
following: mechanical integrity of the muscle cells, autophagy or apoptosis. In these filaments,
we find that the likely mechanism of force improvement is due to mechanical softening of the
cells that occurs due to f-actin depolymerization. This softening lowers the internal mechanical
barrier to contraction. In order to rule out potential non-mechanical origins of the
improvement in force, we measured changes in gene expression of sarcomeric proteins,
energetic metabolism genes, protein production and degradation genes. We also measured
changes in energetic activity that may have contributed to the force improvement as revealed
by changes in AKT phosphorylation, glucose consumption, cellular metabolism and
mitochondrial activity. None of these non-mechanical factors changed significantly with f-actin
disruption, supporting our hypothesis that the force improvement is due to mechanical
softening. Given the obvious contractile improvement observed upon their disruption, we
investigated why these f-actin filaments were present to start with. We found that they may
improve the fatigue resistance at the cost of reduced contraction.
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On the other hand, depleting other non-sarcomeric f-actin structures that are ARP2/3
mediated or tropomyosin (Tpm3.1) stabilized were found to have a deleterious effect on
skeletal muscle contraction. These actin filaments seem to be "beneficial" to muscle
function. We hypothesize that these are among the filaments that help transmit the sarcomeric
force to the costameres and eventually helping perform external work. Future studies are
warranted to tease out this behavior further.
Both these are novel findings that have finally revealed the role of the non-sarcomeric f-
actin, decades after the discovery of sarcomeric acto-myosin contraction in muscle. If these in
vitro and ex vivo findings are proven to be true in vivo, we may open doors to a whole new
family of f-actin based therapies of muscle disorders.
We conclude this thesis by demonstrating an application and proposing several new
studies to translate these discoveries.
5.2 Changes in engineered biological robot walking
5.3 Hypothesis: f-actin disruption could improve skeletal muscle
powered walking
In chapter 2, we have conclusively shown that f-actin disruption improves muscle active
contractility as measured by the optogenetically induced peak twitch force. So what? What
does this mean functionally for skeletal muscle function in vivo?
One hypothesis is that it could make patients with weak skeletal muscles walk better. Testing
this method in vivo even in a live animal model is currently neither ethical (as most of the f-
actin disrupting compounds that we use have significant cardiotoxicities) not feasible as it is
not targeted well to just skeletal muscle. In order to test this hypothesis in an in vitro model
simulating walking, we used a recently developed next generation functional assay for skeletal
muscle powered walking84 .
5.3.1 Experimental model
The model is a C2C12 skeletal muscle based biological robot that uses a walking mechanism
similar to an inchworm (which is one of the simplest examples of skeletal muscle powered
motion). A hydrogel backbone is 3D printed that serves as the skeleton in "skeletal muscle".
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Ring-shaped C2C12 based muscle rings are fabricated on ring shaped negative molds of ABS.
These are then transferred to the skeleton.
Detailed step-by-step fabrication methods for the muscle powered biobot fabrication are
described elsewhere 106. But briefly, a commercial stereolithographic 3D printing apparatus
(SLA 250/50; 3D Systems) was used to 3D print hydrogel based muscle ring molds (Fig. 58)
with parts designed using CAD software (Solidworks). The biobot ring molds were fabricated
on glass slides using a prepolymer solution composed of 20% (wt/vol) PEGDMA MW 1,000
g/mol (Polysciences) in PBS (Lonza) with 0.5% (wt/vol) 1-[4-(2-hydroxyethoxy)phenyl]-2-
hydroxy-2-methyl-1-propanone-1-one photoinitiator (Irgacure2959; BASF) dissolved in
DMSO. The walking bio-bot skeletons were fabricated on glass slides using a prepolymer
solution composed of 20% (vol/vol) PEGDA MW 700 g/mol (Sigma-Aldrich) in PBS with 0.5%
(wt/vol) Irgacure 2959 photoinitiator dissolved in DMSO. Following fabrication, molds and
bio-bot skeletons were rinsed in PBS, sterilized in 100% ethanol (Decon Labs) for 1 h, and
stored in PBS for at least 1 h before use. For parts that required chemical tethering to the
underlying slides, the glass was pretreated with 2% (vol/vol) 3-(trimethoxysilyl) propyl
methacrylate (Sigma-Aldrich) in 100% ethanol for 5 min, washed in 100% ethanol for 5 min,
and baked at 110 'C for 3 min.
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Fig. 58: Biobot fabrication process involving 3D printed hydrogel molds, molding optogenetic
skeletal muscle and assembly of the bio-hybrid structure.
C2C12 based biobot rings were made by molding a cell gel solution in the ring molds. The
composition of the cell gel is 1OM/ml C2C12-ChR, with 30% matrigel in a 4mg/ml fibrin gel,
made by cross linking fibrinogen (SigmaAldrich) with 2ui/ml thrombin. The muscle rings were
transferred from the ring molds to the bio-bot walker molds using a pair of precision tweezers.
They were incubated in GM+ (DMEM + 10% FBS + PS + ACA) for 3 days, and then switched to
differentiation medium DM+ (DMEM + 4% HS + PS + AA + SOng/ml mIGF1) for 12 days .After
this, the bio-hybrid muscle/skeleton construct was dislodged from the glass slide and placed
on a petri dish filled with warm DM+ medium. Thereafter, the twitching and walking assays
were conducted.
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A tetanic pulse (just like in Chap 2) was applied at 1Hz frequency and the twitch length (active
displacement of the cantilever was observed), while the biobot sits on its "back" - the curved
convex side of the skeleton, thereby minimizing friction for the twitch. When the biobot sits on
its legs, it could exhibit net translation because of the asymmetric structure of the skeleton
(Fig. 58, 59A). However, if the muscle is too weak, translation is not observed. C2C12 based









contraction Relaxed again with no net translation
Untreated biobot exhibits weak twitches each second with no net translation
time =0 to is
CytoD
treated
biobot .W LCytoD treated biobot walks robustly with each twitch resulting in a net translation
time = 0 to 100s
Fig. 59: CytoD treatment increases the twitch length of a weak biobot and this improvement
also results in translation of the biobot (which was so weak prior to treatment that it didn't
exhibit net translation upon optogenetic stimulation). The yellow lines are fixed and were
overlaid on the timelapse for easier visualization of the translation.
5.3.2 Results
As shown in Fig. 59B, CytoD treatment (3iM) for 1 hour led to a statistically significant
improvement yet modest (-40%) improvement in twitch length (defined as the change in net-
separation between the tips of the two legs) of biobots sitting on their "back". We say modest
because the active force improvements we observed in Chapter 2 are -150%.
However, even this modest improvement was sufficient to cause a dramatic improvement in
walking of biobots sitting on their legs. These biobots were stimulated continuously with once
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a second with a 30Hz 5ms ON blue light pulse like before. As shown in Fig. 59C, prior to f-actin
disruption, the biobot was so weak that it would simply twitch weakly, without exhibiting any
net translation. However 1 hour after CytoD treatment, it starts translating across the field of
view.
5.4 Future studies
5.4.1 Recovery offunction in muscle disease models
There is a range of skeletal muscle disorders such as muscular dystrophy (MD) and muscle
wasting that could be modeled using our system described in Chapter 2. It would be
interesting to test if f-actin disruption could be a potential new therapeutic option for any of
these disorders.
MD refers to a group of muscle disorders that increasingly result in weaker muscle and muscle
breakdown over time. The most common MD is Duchenne Muscle Dystrophy which is of
genetic origin. It is also a common side effect of hyperlipidemia drugs (statins). Currently there
are no cures for MD and treatments including physical therapy and corrective surgery have
poor outcomes. Studying MD with our system would be a very feasible follow-on study as there
are many ways to model MD, using chemically (statins, tropomyosin inhibitors etc.) and
genetically inducible methods (targeting the dystrophin gene). Likewise, there are well
established models of muscle wasting, for instance glucocorticoid induced that could be used
to develop a Sarcopenia model.
5.4.2 Drug delivery system
For this study to be a useful model for muscle disorders, we need to develop methods to
disrupt f-actin in only skeletal muscle, as systemic f-actin disruption could lead to fatal
toxicities (eg. Cardiotoxicity). The following 3 options could potentially be fruitful starting
points for targeted delivery of f-actin disrupting therapies to skeletal muscle. 1) The use of
actin disrupting agents encapsulated within muscle targeted nanoparticles, 2) adeno-
associated viruses that skeletal muscles uptake preferentially as well as 3) viral gene therapies
that deliver f-actin disrupting genes (gelsolin, cofilin etc.) with skeletal muscle specific
promoters. This is an area worth investigating further.
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5.4.3 Targeted f-actin disruption
CytoD, Latrunculin etc. are toxic chemicals. In order for f-actin disruption to become an
effective therapeutic, we must find safer methods of f-actin disruption.
Actin binding proteins such as Profilin and Cofilin (described in Section 3.6), are alternate
targets that could be used for f-actin disruption. Inhibiting Profilin may slow the rate of
addition of G-actin monomers to the barbed end of dynamic f-actin filaments. Overexpressing
Coflin may severe f-actin filaments. We may also screen for actin binding protein isoforms that
may be skeletal muscle specific in order to prevent the off skeletal muscle toxicity.
Alternatively, we could fin novel targets by using Si-RNA and/or CRISPR libraries to find novel
targets that may allow translation of the f-actin disruption phenomenon described in this
thesis in to a therapeutic.
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Appendix 1: Primer sequences for RT-PCR used in Sec. 2.4.2
and 4.2
Mouse primer sequence for real-time RT-PCR.
Target Gene Forward primer sequence Reverse primer sequence
(5'-3') (5'-3')
Actgl AATCGCCGCACTCGTCATT CCCTACGATGGAAGGGAACAC























Appendix 2: Code for cantilever edge detection
# Import packages
# Import packages
#importing some useful packages
import matplotlib.pyplot as plt
import matplotlib.image as mpimg









import pandas as pd





Applies an image mask.
Only keeps the region of the image defined by the polygon
formed from 'vertices'. The rest of the image is set to black.
#defining a blank mask to start with
mask = np.zerosjlike(img)
#defining a 3 channel or 1 channel color to fill the mask with depending on the input image
if len(img.shape) > 2:
channelcount = img.shape[2] # i.e. 3 or 4 depending on your image
ignore-maskcolor = (255,) * channelcount
else:
ignore.maskcolor = 255
#filling pixels inside the polygon defined by "vertices" with thefill color
cv2.fillPoly(mask, vertices, ignore maskcolor)
#returning the image only where mask pixels are nonzero
maskedimage = cv2.bitwiseand(img, mask)
return masked-image
# MAIN FUNCTION FOR CANTILEVER DIPLACEMENT TRACKING
# INPUT: Name of cantilever videos folder
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# OUTPUT: Max displacement vectorfor all videos
# TUNABLES: image roi, auto-thresholding selection locations
def cantilever-disp(img-dir, display = False, thresh = 0.8):
###################################################




os.makedirs(img-dir+"results") # to store some results
cantilevermax.disps = [] # store each video's max displacemen here
print ("starting to process videos in " + img.dir)
for fileindex,filepath in enumerate(sorted(glob.glob(img-dir+ "*.avi"))):
print (filepath)
timestr = time.strftime("%Y%m%d-%H%M%S") #to name image results
###################################################
# Read in video and convert to an image array
###################################################
reader = imageio.getjreader(filepath)
frames = [] # this stores the video as an array of images
# video has non-duplicate frames in locations 0, 3, 7, 11, 15, 19
frame = reader.get-next-data()
frames.append(frame) # storeframe 0




# FOR EACH IMAGE, EXTRACT THE BOUNDA RIES
###################################################
cantilever-edges = [] # array of slope-intercept values of all lines
n_frames = len(frames)
print("total frames = %d"%(nframes))
for i in range(n-frames-1):
# for i in range(90,110):
img = frames [i]
#plt.imshow(img)
#print(img.shape)
img-grey = cv2.cvtColor(img, cv2.COLORRGB2 GRAY)
#img norm = cv2.equalizeIlist(img-grey)
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# Estimate threshold for each video frame
if i == 0:
img-width = img-grey.shape[1]
img-greyjleft = np.median(img-grey[:, :30].flatten().astype(float))
img-grey-right = np.median(img-grey[:, (img-width-40):].flatten(.astype(float))
#img-greyjleft = img-grey.flatten(.astypeUfoat).min()
#img-grey right = imggrey.flatten(.astype(float).max()
threshold = thresh*imggreyjleft + (1-thresh)*img-grey-right
#imgnorm = np.maximum(((img-grey.astype(float) - 1.1 *img grey left)
# /(0.3*imggrey right-0.4*imggrey left)*255), 0).astype(np.uint8)
img-norm = cv2.GaussianBlur(img-grey, (15, 15), 0)
# use an edge preserving filter here since our measurement depends on the edge
for j in range(5):
img-norm = cv2.medianBlur(img-norm, 7) # Median filtering
#print ("threshold in frame %d is %f"%(i,threshold))
img-norm = (img.norm < threshold).astype(np.uint8) # Thresholded
edges = cv2.Canny(img-norm, 0, 1) # Edge detection
#edges = cv2.Canny(img-norm, 20, 60)
# define ROI that covers cantilever edge, cut out the boundaries
vertices = np.array([[[5,10],[(img-width-20),10], \
[(imgwidth-20),290],[5,290]]], dtype=np.int32)
edgesinjroi = region-ofinterest(edges, vertices)
# APPLY HOUGH TRANSFORM
rho = 2 # distance resolution in pixels of the Hough grid
theta = np.pi/180 # angular resolution in radians of the Hough grid
thresholdhough = 10 # minimum number of votes (intersections in Hough grid cell)
minline-length = 20 #minimum number of pixels making up a line
maxline-gap = 25 # maximum gap in pixels between connectable line segments
lines = cv2.HoughLinesP(edgesin_roi, rho, theta, threshold_hough, np.array([]), \
minLineLength=min line_length, maxLineGap=max-line-gap)
# Adaptively fit Hough Transform to the videos if a longer line can't be found
if lines is None:
while (lines is None):
min-linejlength -= 5
if minlinelength == 0:








plt.imshow(edges, cmap = 'gray')
plt.subplot(1,5,4)
plt.imshow(edges, cmap = 'gray')
plt.subplot(1,5,5)
plt.imshow(edges, cmap = 'gray')
return cantilevermaxdisps
else:
lines = cv2.HoughLinesP(edgesin_roi, rho, theta, threshold, np.array([]), \
minLineLength=min line_length, maxLineGap=maxjline-gap)
# plot lines on original image
lineimg = np.zeros((img.shape[O], img.shape[1], 3), dtype=np.uint8)




for line in lines:
for (xl,yl,x2,y2) in line:
cv2.line(line-imgl, (xl,yl), (x2,y2), [0, 255, 0], 1) # plot all hough lines








# interchanged x andy; because most lines are close to vertical
# this will givex= my + c




if res>2: # The 2 is tunable







for countix_val in enumerate(x-line):






weightsnorm = weights-line-temp/np.sum(weights linetemp)
line1, res, _, _, _ = np.polyfit(y line-temp, xlinetemp, deg=1, w=weights-norm, full = True)
ifres < 1:
print ("correctly captured with res " + str(res))
else:
print ("could not capture with res" + str(res))
if display==True or i==0:
# plot just the finalfitted line on original image
cv2.line(line-img, (int(img.shape[0]*line1 [0]+line i[11),img.shape[0]), \







plt.imshow(edges, cmap = 'gray')
plt.subplot(.,5,4)
plt.imshow(cv2.addWeighted(line-imgl, 0.8, img, 1, 0))
plt.subplot(1,5,5)
plt.imshow(cv2.addWeighted(line-img, 0.8, img, 1, 0))
plt.suptitle("frame %d "%(i+1)+ filepath[-21:] + " %f"%(line1[1]) +" residual" + str(res/l
en(xjline)))
if i==0:
plt.savefig(img-dir+"results/"+"edge" + "%d"%(file-index+1) + ".jpg", \
bboxinches='tight', pad-inches = 0, dpi=400)
cantilever..edges.append(line1)
#print ("processed frame %d"%(i+1))
print ("Processed %d frames"%(n-frames-1))
###################################################
# Aggregate image edges and compute displacements
################################################ ###




mslope = cantilever_edges[:,0].mean() # meancantilever slope
# note: here mslope = tan(theta) is dx/dy
# also 1 px = 0. 644um
x-disp = [(x - xintercepts[O])/(1+math.pow(mslope,2))*0.644 for x in xintercepts]
np.savetxt(img-dir+"results/"+'disp' + "%d"%(file_index+1) + '.csv', x-disp, delimiter=',')




# Plot displacement as a function of time
plt.figure()
plt.plot(x-disp) # note the two twitches
plt.title("Max disp = %.2f um"%(xmax))
plt.ylabel("Cantilever displacement (in microns)")
pIt.savefig(img-dir+ "results/"+"cant-disp_" + "%d"%(fileindex+1) + ".jpg", \
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